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ABSTRACT 
Background: Eczema (atopic dermatitis) is an itchy inflammatory skin disease that affects many 
children and adolescents. Eczema associated with IgE antibodies is called atopic eczema (AE), while 
other eczema is called nonatopic eczema (non-AE). Having a filaggrin (FLG) mutation is associated with 
increased risk for eczema. Children with eczema more often develop food allergy, asthma, and rhinitis. 
It has been suggested that eczema is associated with non-allergic comorbidities such as ADHD. 
Aims: To describe eczema in adolescence and the course of preschool eczema up to age 16 years in a 
population-based birth cohort, to investigate consequences of preschool eczema and FLG mutation 
later in childhood/adolescence and to study factors of importance for remission of preschool eczema. 
Methods: We used data from a Swedish birth cohort recruited from the general population (n=4,089). 
The families provided information on background factors at inclusion when children were 2 months of 
age. Questionnaires regarding eczema during the preceding year were answered by parents at 1, 2, 4, 
and 8 years, and by parents and children at 12 and 16 years. Information on IgE sensitization at 4, 8, 
and 16 years and on FLG mutation was available for most children. Record-linkage to the Swedish 
prescribed drug register provided data on dispensed medication at age 10-18 years (range 8.6-19.9). 
Results: The 12-month prevalence of eczema in adolescence was 10%, and of those affected 73% had 
mild, 17% moderate, and 10% severe eczema. The most common locations of eczema in adolescence 
were flexural surfaces (73%), neck (40%) and extensor surfaces of extremities (39%). Among 
adolescents with eczema, onset was most common before age 2 years (49%), but onset after age 12 
years was also common (26%). A history of eczema at every previous follow-up was seen among 11% 
of the adolescents with eczema. In adolescence, AE was more common, had earlier onset and was 
more severe compared with non-AE, but there were no differences in seasonal variation or location 
of eczema. 
There was no association between PSE and ADHD medication at school age (adjOR 1.12, 95% CI: 0.80-
1.56). Further, PSE was not associated with dispensed antidepressants, migraine medication or 
antiepileptics at school age. 
PSE was associated with IgE sensitization to both food and aeroallergens up to age 16 years (overall 
adjOR 2.30, 95% CI: 2.00-2.66). This association was significantly stronger among children with 
persistent PSE. Among sensitized children at age 4, 8, and 16 years, polysensitization was more 
common in children with PSE than those without PSE. FLG mutation was not associated with IgE 
sensitization up to age 16 years, with the exception of IgE sensitization to peanut at age 4 years (adjOR 
1.88, 95% CI: 1.03-3.44). 
Half (51%) of children with PSE were in complete remission of eczema at school age. In prognostic 
multivariate models male sex and exclusive breastfeeding ≥4 months were positively associated with 
complete remission of PSE at school age. Persistent PSE, severe PSE, parental allergy, parental 
smoking, and FLG mutation were associated with reduced likelihood of complete remission. The 
prognostic models developed had correct classification rates of 63-65%. 
Conclusions: Only half of children with eczema before age 4 years are in complete remission at school 
age. Of adolescents with eczema, more than 10% have severe eczema. In adolescence, AE and non-AE 
do not differ in seasonal variation or location. No significant association was found between eczema 
and dispensed ADHD medication, antidepressants, migraine drugs or antiepileptics. PSE, especially if 
persistent, is strongly associated with IgE sensitization to both foods and aeroallergens. FLG mutation 
is associated with IgE sensitization to peanut, but not to other allergens, indicating that FLG mutation 
in the absence of PSE does not play a major role in IgE sensitization. Finally, male sex and exclusive 
breastfeeding ≥4 months were positively associated with complete remission of PSE at school age, 
whereas persistent and/or severe PSE, parental allergy, parental smoking, and FLG mutation were 
associated with reduced likelihood of complete remission. 
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1 BACKGROUND 
ECZEMA 
Nomenclature 
The clinical features of eczema are highly variable and there is no specific diagnostic test to 
verify the disease group. Because of this the nomenclature for eczema is divergent, and atopic 
dermatitis and atopic eczema are often use synonymously with eczema. Therefore, the 
nomenclature used in research, as well as in clinical practice, can be confusing. 
According to the World Allergy Organization (WAO) nomenclature established in 2004, the 
umbrella term for local inflammation of the skin should be dermatitis. Eczema is the term 
describing dermatitis with certain clinical characteristics and association with atopic diseases 
(asthma and rhinitis). If a skin prick test or analysis of IgE antibodies in serum is performed, 
eczema can be classified as atopic eczema (presence of IgE sensitization) or nonatopic eczema 
(absence of IgE sensitization).1 
 
 
Figure 1 WAO nomenclature of eczema.1 
 
In literature, the terms eczema, atopic eczema (in the UK) and atopic dermatitis (in the USA) 
are used synonymously, and in clinical practice atopic eczema and atopic dermatitis are often 
used even when a patient has not been tested for IgE sensitization.2 Within this thesis, we 
have chosen to use the WAO nomenclature as no other consensus is established. In 1980, 
Hanifin and Rajka described the main clinical criteria of eczema (atopic dermatitis), based on 
patients seen in hospitals,3 and these criteria have been widely used and refined thereafter. 
The most validated diagnostic criteria of eczema, often known as William´s criteria, were 
developed by a UK working party.4-8 These are commonly used in every-day clinical practice, 
in clinical trials and in epidemiological studies, see Table 1. 
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Table 1 William’s criteria for atopic dermatitis. 
MUST have itchy skin condition in past 12 months 
PLUS three or more of: 
1. History of involvement of the skin creases 
2. Personal history of asthma or hay fever, or if child <4 years, history of atopic disease in 1st 
degree relative 
3. History of generally dry skin in past year 
4. Visible flexural dermatitis 
5. Onset below age 2 (not used if child <4 years) 
The UK refinement of Hanifin’s and Rajka’s diagnostic criteria for atopic dermatitis (for use as 12-month 
prevalence measure in epidemiological studies).9  
 
Clinical presentation 
Eczema is a relapsing inflammatory skin disease characterized by skin dryness, scratching and 
itchy red rash that favors the body folds.10 Disease onset is most common in the first two 
years of life but many debuts later in childhood, adolescence or in adulthood.11, 12 Episodes 
with red, scaly and itchy patches or plaques are followed by periods free from symptoms. 
Eczema is most common early in childhood, and the episodes of symptoms in general 
becomes less frequent later in childhood and among adults. Rash distribution on the bodies 
of individuals with eczema is highly variable and age-bound. Therefore, eczema is classified 
into three different phases.11, 13, 14  
 The infantile phase (up to 2 years of life); with skin lesions on the face, neck, 
extensor surfaces of extremities and on the trunk.  
 The childhood phase (between 3 and 11 years); involvement of body folds, face 
(mostly perioral and not as common as in the infantile phase), as well as hands, feet, 
buttocks and on the back/inside of the thighs.14  
 The adult phase (from 12 years); mainly involving body folds, face (mostly 
forehead/periorbital), neck and hands.11, 15, 16  
This classification is based on patients seen in hospitals with more severe disease. However, 
most individuals with eczema are treated in primary care; furthermore, it has been shown 
that about 30% of Scandinavian school-children with eczema and other allergy-related 
diseases have never visited a doctor for their symptoms.17 The characteristics of eczema 
among adolescents in the general population have not been described in detail, although 
eczema is common in adolescents. 
Atopic (AE) and nonatopic eczema (non-AE) 
IgE sensitization is not causative, but follows in the course of infantile eczema.18-20 Many will 
never develop IgE sensitization, but still have typical signs of eczema. This non-IgE-associated 
form of eczema, non-AE, is not associated with atopic asthma and is more common among 
females.21 The classification of AE includes presence of IgE antibodies to either food or 
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aeroallergens.1 Non-AE in children may evolve into AE, and the diagnosis of AE and non-AE 
cannot be reached without an IgE antibody determination or skin prick test.1 A study among 
5-year-old children suggests that AE and non-AE are two different entities; (i) the AE variant 
is more common, presents early in infancy, has a male majority and is more persistent, and 
(ii) the non-AE variant goes with later onset and has no relation to asthma or hay fever.22 
Others argue that IgE sensitization is associated with an increased risk of more severe and 
more persistent eczema, but that it is not a useful diagnostic tool when other clinical signs 
have been taken into account.23 
Differences between AE and non-AE regarding disease course, eczema severity and clinical 
characteristics in the general population need further exploration. 
Outcome measures 
The Harmonizing Eczema Outcome Measures (HOME) initiative was started in 2010 as an 
effort to provide consensus regarding what diagnostic criteria and outcome measures to use 
within eczema research, in particular in clinical trials. The outcome measures used up until 
then had been diverging and often not validated making it difficult to compare result from 
different studies.24 The HOME initiative identified clinical signs, symptoms, quality of life, and 
long-term control of flares as core outcome domains for eczema trials. The most validated 
scales for clinical signs are the Eczema Area and Severity Index (EASI) and the objective Scoring 
Atopic Dermatitis (SCORAD). A recent systematic review recommended EASI for clinical signs 
in future studies.25 Moreover, the HOME initiative has proposed that the Patient-Oriented 
Eczema Measure (POEM) be used for assessment of symptoms.26 POEM reflects symptoms in 
the week before assessment and should be used in trials, but due to the intermittent course 
of eczema POEM does not reflect the symptoms or severity of eczema over the course of the 
preceding year. An alternative in epidemiological studies could be the validated Nottingham 
Eczema Severity Scale (NESS), assessing symptoms in the preceding 12 months.27 NESS has an 
adequate interobserver reliability, but is not tested sufficiently and has not performed 
adequately according to a systematic review.28 In the BAMSE project, the BAMSE Eczema 
Severity Score (BESS) was developed in the 12-year follow-up. BESS has not been validated, 
but it is similar to NESS.29 
Epidemiology 
The prevalence of eczema has increased in Sweden and in other industrialized countries 
during the past decades; 15-30% of children and 2-10% of adults are affected.10, 30 The 12-
month prevalence of eczema in adolescence is 7.3%-13%.31-35 In the International Study of 
Asthma and Allergies in Childhood (ISAAC) phase 3, the global 12-month prevalence at 13-14 
years of age was 7.3% and the Swedish prevalence 12.3%.31 In the 12-year follow-up in the 
BAMSE project the prevalence of eczema was 11.9%,29 and in a British birth cohort, from the 
Isle of Wight, the prevalence at 18 years of age was 12.3%.35  
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Although the natural course of eczema in children and adolescents is individual, eczema often 
debuts in childhood.18, 36 More than 60% have disease onset within the first 2 years of life11, 21 
but onset can occur in any age.12 For example, in the British National Child Development Study 
(NCDS) 28.4% of 16-year-old subjects with eczema reported that their eczema onset was after 
age 7 years.37 
Since eczema is most common in early childhood, children are said to “grow out” of their 
disease. It has been suggested that about 60% of children with eczema are free from 
symptoms in early adolescence.2 This has been confirmed in three European birth cohorts,18, 
35, 38 in which approximately half of children with infantile eczema were in remission later in 
childhood. However, up to 40-60% may have recurrence later in life, often as hand eczema.16, 
39, 40 Among adults who had visited a Swedish hospital outpatient clinic because of eczema, 
59% still had eczema 24-38 years later.41  
Factor of importance for prognosis of eczema 
Knowledge of disease prognosis is important, especially for parents of small children with 
eczema, and several prognostic factors have been identified.9 Early-onset eczema,40, 41 IgE-
mediated sensitization,18, 40, 41 family history of eczema,18, 41 and severe eczema in childhood18, 
40 have all been reported to be associated with worse prognosis. Sex has not been found to 
be a prognostic factor.18, 41 In a recent systematic review and meta-analysis, Kim et al 
concluded that onset before age 2 years, and male sex was associated with better prognosis 
while persistent disease was associated with worse prognosis. Presence of IgE sensitization 
was not associated with persistent disease.42 Most studies have focused on eczema early in 
life and subsequent disease course in childhood, but less is known about children with eczema 
onset later in childhood or in adolescence. The first systematic review investigating which 
factors that predict remission of infantile eczema was published in 2015. Only two studies 
were suitable for inclusion and the authors concluded that it is largely unknown which factors 
predict remission of infantile eczema.43 The natural course and prognostic factors require 
further study. 
Etiology 
Briefly, two major pathophysiological aspects initiate eczema: abnormalities of skin barrier 
structure or function and cutaneous inflammation due to an inadequate immune response.12 
Each aspect can cause eczema alone, but in most cases eczema is probably caused by a 
combination of epidermal dysfunction and hyper-reactive immune response causing 
inflammation. Both aspects can be triggered by predisposing genetic factors and/or 
environmental factors.44 
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Genetics 
Heredity is a known risk factor for eczema. In a Danish twin study, the concordance rate was 
much higher in monozygotic twins (72%) than in dizygotic twins (23%).45 Allergic asthma and 
allergic rhinitis in a parent seem to be of minor importance for the development of eczema in 
the offspring, indicating that eczema might be inherited independently.46 The strongest 
known genetic factor is loss-of-function mutation in the filaggrin gene (FLG),12 see below 
(page 14). 
Environment 
Genetics alone cannot explain the increase of eczema seen over the world.47 Environmental 
factors have been found to play an important role in eczema development. For example, 
eczema is more common in wealthy families.48 Black Caribbean children living in London have 
higher prevalence of eczema than children with the same ethnicity living in Kingston, Jamaica 
(14.9% vs. 5.6%).2  
In 1989, David Strachan found that eczema was less common in large families, and in younger 
siblings. This led to “the hygiene hypothesis”, i.e. that younger siblings in large families are 
more exposed to infections and thereby protected from atopy and atopic disease 
manifestations.49 While many studies have been conducted, the hygiene hypothesis has not 
been confirmed and there is no clear evidence of protective effects of early life infections on 
development of eczema. Flohr et al performed a systematic review including studies inspired 
by the hygiene hypothesis evaluating risk factors for eczema. They concluded that there was 
an inverse relationship between eczema and early day care, consumption of unpasteurized 
milk, and farm animal and dog exposure in early life. The protective effects of these, as well 
as the fact that use of broad-spectrum antibiotics increased the risk of eczema, was thought 
to be due to a general increase in exposure to non-pathogenic infections.50 They also found 
that cat exposure in combination with impaired skin barrier is associated with an increased 
risk of eczema, and that routine childhood vaccinations are not associated with a risk of 
eczema. Helminth infection is protective for eczema, but bacterial and viral infections are 
not.50 Several studies have investigated whether prebiotics (non-digestible food ingredients 
that promote the growth of beneficial microorganisms in the intestines) or probiotics (live 
microorganisms assumed to provide health beneﬁts to the host when consumed) can prevent 
incident eczema. A systematic review and meta-analysis have shown that probiotics given to 
pregnant or breastfeeding women and/or infants reduced incident eczema,51 while the 
evidence for prebiotics is more uncertain, though some studies indicate that prebiotics given 
to high-risk infants might prevent eczema.52 Passive exposure to tobacco smoke is associated 
with increased risk for eczema.53 To summarize, probiotics may be protective for eczema.54 
In contrast, small family size, high education level in household, smoking in household, and 
living in regions with low humidity and low exposure to ultra violet radiation are associated 
with increased risk for eczema.12, 53  
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Treatment 
The aim of treatment is to improve symptoms and achieve long-term disease control. The 
main principle is continuous epidermal barrier repair with use of emollients and avoidance of 
individual trigger factors.12 Use of emollients in patients with eczema extends the time to 
relapse, and give longer disease-free periods.55 The hypothesis that use of emollients can 
prevent, or delay, eczema onset has emerged in the last few years due to increasing research 
evidence that epidermal dysfunction has a pathogenic role in eczema. In a  randomized clinical 
trial, Simpson et al found that daily use of emollients in high-risk newborns (treatment started 
within 3 weeks of age) reduced the risk of developing eczema at 6 months of age (RR 0.50, 
95% CI: 0.28-0.9).56 Similarly, Horimukai et al showed that daily application of emollients 
during the first 32 weeks of life reduced the risk for eczema in high-risk infants.57 Larger, 
ongoing trials to analyze the possible preventive effect of emollients will hopefully clarify this 
further. 
Topical glucocorticoids (TGCs) are the first-line anti-inflammatory treatment to control acute 
exacerbations.12, 58 The treatment is used daily during flare-ups until good clinical response is 
achieved (reduction of itch). When the itch has disappeared, dose tapering is initiated and 
made gradually, so as to avoid the withdrawal rebound phenomenon.59 Most TGCs have been 
used twice daily, but recent studies have shown that with potent TGCs and newer 
preparations, application once daily is equally effective.60 Proper use of TGCs entails a small 
risk of adverse events. The risk of skin atrophy, when TGCs are used for between 4 weeks and 
1 year, is 0-5%61 and in a large systematic review of clinical trials was found to be 0.8%.58 Twice 
weekly application of fluticasone reduces the risk of relapses and might be used to maintain 
clearance.62 
Topical calcineurin inhibitors (TCIs) are non-steroid anti-inflammatory agents and considered 
as the second-line option for intermittent and short-term use.12 TCIs do not induce skin 
atrophy, in contrast to glucocorticoids and are therefore suitable for certain locations, such 
as the face and the genital area.59 However, few studies have compared the new TCIs with 
conventional therapy (TGCs). A recent systematic review showed that TGC and TCI had similar 
rates regarding improvement of dermatitis and successful treatment. TCI was associated with 
higher costs and more adverse events (skin burning and pruritus). There were no significant 
differences in skin atrophy or skin infections. The review concluded that TGC is the therapy of 
choice in eczema.58 
If eczema cannot be controlled through topical treatment, phototherapy should be 
considered. When topical treatment and phototherapy fail, systemic immunosuppressive 
treatment is required, in both children and adults.12 Cyclosporine, mycophenolate mofetil, 
methotrexate, and azathioprine are the best studied agents in children,63 but promising 
newer targeted biologic therapies are under development for adults.64 
 14 
FILAGGRIN MUTATION 
For ichthyosis vulgaris, a skin disease characterized by dry and scaly skin, loss-of-function 
mutations in FLG have been identified as causal factor.65 These mutations were also found to 
be strongly associated with eczema; in the families with ichthyosis vulgaris, eczema was 
present in 44% of individuals heterozygous for these loss-of-function mutations of the FLG 
gene and in 76% of individuals with both alleles mutant. None of the family members without 
FLG mutation had eczema. The conclusion was that FLG mutations leading to impaired skin 
barrier function are closely linked to eczema and to allergic asthma in individuals with 
eczema.10, 66 Subsequent studies have confirmed FLG mutations as a major risk factor for 
developing eczema.66-69 In addition, studies have shown that FLG mutation is associated with 
more persistent disease,70-72 while others have not found a significant association.73, 74 
However, the majority of people with eczema do not have any FLG mutation and up to 60% 
of individuals with FLG mutations will never develop eczema.12  
Having a FLG mutation is associated with other allergy-related diseases. For example, FLG 
mutation is associated with asthma among children with eczema or a history of eczema,70, 75 
and with allergic rhinitis in some studies.69, 75 Furthermore, an early systematic review and 
meta-analysis concluded that FLG mutation is associated with increased risk for developing 
IgE sensitization.69 It has been suggested that this association could be explained by a 
defective skin barrier function allowing penetration of allergens, which induces IgE 
sensitization.76-78 This hypothesis is supported by the finding that FLG mutation in the absence 
of eczema is associated with both IgE sensitization to peanut and peanut allergy.79, 80 
However, more recent studies that have evaluated the relation between FLG mutation and 
IgE sensitization and included eczema as a covariate present conflicting results.70, 81-84 Further 
exploration of the association between IgE sensitization and FLG mutation, with a possibility 
to adjust for eczema, is needed. 
IGE SENSITIZATION 
IgE sensitization occurs when the immune system produces IgE antibodies, which can be 
detected in the blood. This can be initiated as a response to an allergen. Proteins in foods and 
pollen are common allergens. If an individual with IgE-mediated allergy is exposed to the same 
specific allergen she has IgE antibodies against, organ-specific symptoms may occur. Rhinitis 
induces symptoms from the nose (itching, sneezing, increased secretion and blocking), 
asthma symptoms from the lungs (wheezing, cough, and forced breathing), and, if the skin is 
involved, eczema or urticaria will occur. IgE sensitization also exists among individuals without 
allergic disease.85  
Children with eczema have increased risk for IgE sensitization to foods.86-88 This association is 
even stronger with a more severe eczema,82 and persistent eczema.89 Less is known regarding 
the association between eczema and IgE sensitization to aeroallergens. The Isle of Wight 
cohort reported that eczema was associated with IgE sensitization to aeroallergens at age 4 
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years.86 The temporal relationship between eczema and IgE sensitization is not fully 
established, since very few larger studies have tested for IgE sensitization before eczema is 
diagnosed the first time. However, a Danish population-based birth cohort followed children 
with regular skin examinations and measurements for IgE sensitization up to 3 years of age. 
Of the children diagnosed with eczema, 43% developed IgE sensitization simultaneously with 
their eczema, 27% showed IgE sensitization prior to or after the eczema diagnosis, and 30% 
did not have IgE sensitization.20 Information on the longitudinal relationship between IgE 
sensitization, either to food or aeroallergens, and eczema from birth up through childhood is 
scarce. The pattern of IgE sensitization among children with early-onset eczema has been 
described,86, 90, 91 but there is limited information on potential differences in the pattern of 
IgE sensitization between individuals with or without previous eczema. 
COMORBIDITIES OF ECZEMA 
Atopy, asthma and rhinitis 
Atopy is a tendency to become IgE-sensitized (produce IgE antibodies) as a response to 
normal exposure to common food or aeroallergens. Individuals with atopy can develop 
symptoms of food allergy, asthma, rhinitis and eczema.1 While asthma, rhinitis and eczema 
are often referred to as allergic or allergy-related diseases, all of them exist in individuals 
without IgE sensitization. As described above, persons with eczema have increased risk for 
IgE sensitization, and food allergy.87 In addition, children with eczema are at increased risk of 
developing asthma and allergic rhinitis.18, 92-94 In a systematic review of 4 birth cohorts, the 
risk for developing asthma was doubled in young children with eczema (OR 2.14, 95% CI, 1.76-
2.75),95 and in a Swedish population-based birth cohort, children with infantile eczema had 
an increased risk of both rhinitis (OR 2.69, 95% CI, 2.22-3.26) and asthma (OR 2.22, 95% CI, 
1.65-2.98) in pre-adolescence.38  
The course and development of allergy-related diseases in childhood have often been 
referred to as the atopic march. Eczema is the first clinical manifestation, followed by a typical 
sequence of food allergy, asthma, and rhinitis.96 Some of the diseases persist for several years, 
whereas others remit with increasing age.94 The pattern of IgE sensitization changes from 
food allergens to inhalant allergens.33 In 2003, Lack et al demonstrated that use of skin 
preparations containing peanut oil was associated with peanut allergy in children (OR 6.8, 
95% CI: 1.4-32.9). They concluded that IgE sensitization to peanut protein may occur through 
application of peanut oil to inflamed skin.97 Impaired skin barrier function in patients with 
eczema allows penetration of allergens, irritants and bacteria.98 Thus, IgE sensitization to 
allergens may occur via the defective skin barrier and initiate the atopic march.99 Brough et al 
demonstrated that peanut antigen in dust was associated with increased risk of IgE 
sensitization to peanut and peanut allergy in atopic children. The risk was higher in children 
with a history of eczema and severe eczema. This supports the idea of epicutaneous IgE 
sensitization through an impaired skin barrier.100 However, the atopic march does not always 
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follow this classic sequence. For example, patients with asthma may later develop eczema.99 
In a systematic review of several birth cohorts, only 1 of 3 children with eczema in infancy 
developed asthma. The authors stated that the relationship between eczema and asthma 
seems complex and that only a minority of children with infantile eczema follows the 
progression of eczema into asthma as described in the atopic march.95 Thus, it has been 
debated whether the atopic march represents a causal relationship or not. The prevalence of 
having at least two of the diseases eczema, asthma and rhinitis (multimorbidity) varies with 
age. In the BAMSE cohort, the DARC cohort and the MAS cohort the prevalence of 
multimorbidity was 7.5% at 12 years, 12.1% at 14 years and 8.5% at 12 years, respectively.93, 
101, 102 In MeDALL (including 12 ongoing Eurpoean birth cohorts) the corresponding prevalence 
was 4.4% at age 8 years, and multimorbidity was seen among children both with and without 
IgE sensitization. MedALL concluded that IgE sensitization could not be considered as the 
main cause of comorbidity between eczema, asthma, and rhinitis, and that both IgE-mediated 
and non-IgE-mediated mechanisms are probably involved in this multimorbidity.103  
Non-allergic related comorbidities 
In recent years, several studies have shown association between eczema and non-allergic 
diseases, such as malignancies,104, 105 diabetes mellitus type I, rheumatoid arthritis, 
inflammatory bowel disease,106 and, in particular, disorders involving the central nervous 
system (CNS), for example attention-deficit/hyperactivity disorder (ADHD),107-112 depression 
and anxiety disorders,108, 110, 113 and epilepsy.114  
ADHD 
The most studied association is between eczema and ADHD and in a systematic review the 
OR ranged from 1.47 to 7.75. The authors stated that “studies consistently suggest a positive 
association between eczema and ADHD.”115 Later studies have also shown an association 
between childhood eczema and ADHD. For example, a large case-control study (4,692 cases 
and 18,768 controls, OR 1.40, 95% CI, 1.22-1.61)112 and a population-based birth cohort study 
(n=770, RR 1.92, 95% CI, 1.03-3.57) showed an association between eczema at 0-4 years of 
age and ADHD.111 The temporal relationship and underlying mechanisms for this association 
remains unclear. Several possible explanations have been suggested. Inflammatory-released 
cytokines that penetrate the blood-brain barrier and interfere with the maturation of the 
cortex and/or the transmitter system could be involved in the development of ADHD and 
other CNS-associated disorders.116 Another possible explanation is shared risk factors for 
eczema and ADHD. Studies have shown that not only eczema, but also asthma and rhinitis, 
are associated with ADHD,109, 110, 112, 117 and that low socioeconomic status, low birth weight, 
impaired fetal growth, and parental smoking are risk factors for both asthma and ADHD.118 A 
third possible mechanism might be that children with eczema are more prone to develop 
mental and behavioral problems due to their illness.112 Children with chronic disorders such 
as migraine, arthritis and heart diseases more often have emotional and behavioral symptoms 
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compared with the general population.119 ADHD and CNS-associated disorders could be a 
result of the burden of chronic diseases in childhood, with eczema being one of them.108 
Finally, ADHD could be a trigger for eczema. Children with ADHD have psychosocial difficulties 
and higher risk for depression, anxiety, and sleep-disturbance. Psychosocial stress affects the 
severity of eczema.120 
The reported prevalence of ADHD has increased in recent decades and was in a systematic 
review and meta-analysis estimated to 6.7-7.8%.121 ADHD is typically diagnosed in childhood, 
but in most cases symptoms have been present years before diagnosis. Therefore, it is difficult 
to determine the age at disease onset.122 Psychostimulant medication is used for treatment 
of ADHD. In a Swedish study performed in 2006-2011, 83.1-84.7% of children (age 6-17 years) 
with doctor-diagnosed ADHD had used psychostimulants.123 
Most studies evaluating the association between eczema and ADHD have been cross sectional 
and the temporal relationship is still unclear. Large longitudinal studies with prospectively 
collected data are warranted. 
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2 AIMS 
The overall aim was to describe eczema in adolescence and the course of preschool eczema 
up to age 16 years in a population-based birth cohort. Additional aims were to investigate 
consequences of preschool eczema and filaggrin mutation later in childhood and adolescence 
and to study factors of importance for remission of preschool eczema. 
 
In particular: 
To describe adolescent eczema and to identify potential differences in the clinical 
characteristics of atopic eczema and nonatopic eczema in adolescents. 
 
To explore whether preschool eczema is associated with ADHD or other CNS-associated 
disorders requiring pharmacotherapy at school age, and to analyze whether eczema at other 
ages of childhood is associated with ADHD medication. 
 
To examine the longitudinal relationship between preschool eczema, filaggrin mutation, or 
both, and IgE sensitization in childhood. In addition, to investigate if children with preschool 
eczema or filaggrin mutation present different patterns of IgE sensitization than children 
without preschool eczema or filaggrin mutation. 
 
To study the natural course of preschool eczema up to age 16 years, and to identify factors of 
importance for remission of preschool eczema. Lastly, to explore whether prognostic models 
could be useful to predict remission of preschool eczema.  
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3 MATERIALS AND METHODS 
STUDY DESIGN AND SETTING 
All the scientific papers (I-IV) are based on material from the BAMSE (Children Allergy 
Environment Stockholm Epidemiology) birth cohort. The BAMSE project was initiated to study 
risk factors for allergy-related diseases (asthma, eczema, and rhinitis) in the general 
population up to age 4 years. By now, a majority of the children have participated through 
childhood and adolescence and were recently invited to a follow-up at age 22-24 years.  
 
Figure 2 The BAMSE project. Flow chart for the recruitment process until final original cohort. 
The BAMSE birth cohort (I-IV) 
Recruitment started in February 1994 and continued until November 1996. Parents to all 
children born in predefined areas forming a circle sector of greater Stockholm (Northern part 
of inner city, Solna, Sundbyberg and Järfälla) were asked to participate. The selected districts 
were chosen to represent both inner city, urban and suburban households with different 
kinds of buildings and socio-economic status (education and profession). The children and 
their parents were reached through a community-based population register. During the study 
period, 7,721 children were born in the recruitment area. Of these 477 could not be reached, 
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1,256 were actively excluded and 1,399 were non-responders (502 declined to participate and 
897 never answered the baseline questionnaire). The final cohort consisted of 4,089 children 
(75% of the eligible children) whose parents answered the baseline questionnaire when their 
children were aged 2 months old, at median (Figure 2).124  
In 1996, actively excluded families and non-responders were sent a short questionnaire to 
study parental reasons to participate or not in relation to parental allergy, parental smoking 
and keeping pets at home. The response rate was 67%. Parental smoking (at age 2-4 months 
of the child) was more common among non-responders and actively excluded families 
compared with the children in the BAMSE cohort, indicating that life-style factors influenced 
the willingness to participate. However, the willingness to participate was not affected by 
parental allergy or keeping pets in household.124 
 
Figure 3 Description of participation in the BAMSE birth cohort. The longitudinal design 
constituted regular questionnaires and, in addition, clinical examinations with blood sampling 
at 4, 8, and 16 years. 
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The baseline questionnaire (Q0) covered data on residential factors, parental allergy and 
environmental factors. When the children were 1, 2, 4, 8, 12, and 16 years, parents received 
questionnaires (Q1, Q2, Q4 etc.) regarding symptoms of asthma, eczema and rhinitis, 
environmental factors and lifestyle factors. In addition, the children/adolescents received 
questionnaires at age 12 and 16 years (Figure 3). The participants had the possibility to skip 
one follow-up and remain in the study, as long as they did not decline to participate further. 
Children whose parents completed the questionnaires at age 4, 8, and 16 years were invited 
to participate in clinical examinations at the corresponding age including sampling of blood 
specimens.  
The Swedish Prescribed Drug Register (II) 
The Swedish Prescribed Drug Register (SPDR) is a national health care register on all dispensed 
pharmaceuticals. SPDR was established in July 2005 and covers the entire Swedish 
population.125 In the BAMSE cohort, information on prescribed and dispensed medication was 
obtained by record linkage to SPDR (from age 10 years (range 8.6-11.4)) for all children 
included (n=4,089). Data from this register was available through December 31 2013, when 
the participants in the BAMSE cohort were 18 years old (range 17.1-19.9). Linkage was 
performed using the Swedish personal identity numbers.126  
STUDY POPULATIONS (I-IV) 
Study I included 3,108 adolescents who filled out the questionnaire at age 16 years, and 
provided data on eczema (76% of the original cohort). A subpopulation had data on IgE 
sensitization at age 16 years available (n=2,529). 
Study II included 3,606 children with complete data on eczema at age 1, 2, and 4 years (88% 
of the original cohort). A subpopulation encompassed 2,736 children with complete data on 
eczema (parental questionnaires) at age 1, 2, 4, 8, 12, and 16 years (67% of the original 
cohort). Data on dispensed prescribed medication was derived by record linkage to SPDR. 
Study III included 3,201 children with data on eczema at age 1, 2, and 4 years, who provided 
blood at least once at age 4, 8, and/or 16 years (78% of the original cohort). Data on FLG 
mutation was available for 1,890 children in the study population. 
Study IV included children with any eczema reported during the first four years of life and 
data regarding eczema at age 8, 12, and 16 years (n=889). For a majority, data on IgE 
sensitization at age 4 years (n=671) and FLG mutation (n=764) were available. 
DEFINITIONS 
Background variables (I-IV) 
Most background characteristics/exposures were based on questionnaire data reported by 
parents at baseline (when the children’s median age was 2 months) (Table 2). 
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Table 2 Definitions of background factors/exposures used in studies I-IV. 
Variable 
 
Definitiona Study 
Parental allergy 
 
Mother and/or father with doctor’s diagnosis of asthma 
and asthma medication and/or doctor’s diagnosis of hay 
fever in combination with furred pets and/or pollen 
allergy and/or doctor’s diagnosis of eczema (contact 
allergy among parents was excluded). (Q0) 
I, II, III, IV 
Parental smoking 
 
Any parent smoking at least one cigarette per day. (Q0) I, II, III, IV 
Low socio-economic 
status 
 
Both parents were blue-collar workers, or one parent 
blue-collar worker and the other parent was a student, 
housewife, on disability pension or unemployed. (Q0) 
I, II, III, IV 
Exclusive 
breastfeeding ≥4  
months 
 
Infant was breastfed for at least four months, without 
exposure to solid food or formula. (Q1) 
I, II, III, IV 
Any parent born 
outside Scandinavia 
 
Any parent born outside Sweden, Denmark, Norway or 
Finland. (Q8) 
I, II, IV 
Any parent born 
outside Europe 
 Any parent born outside Europe. (Q8)  
Age of mother  Mother's age at birth of child (years). (Q0) I 
Young mother 
 
Mother's age <25 years at birth of child. (Q0) II, IV 
Gestational age 
 
Duration of gestation, reported in weeks. (Q0) I 
Preterm birth 
 
Gestational age <37 weeks. (Q0) IV 
Low birth weight 
 
Weight at birth <2,500g. (Q0) IV 
Older sibling 
 
Any older sibling in household at birth of child. (Q0) IV 
aBased on parental report at baseline (at median age 2 months), at age 1 year or at age 8 years. 
Eczema (I-IV) 
The definition of eczema was based on parental report of either symptoms during the 
preceding 12 months or reported doctor’s diagnosis (Table 3). The questionnaire-derived 
eczema definition has been validated at the pediatric open ward unit of the Department of 
Dermatology, Karolinska University Hospital. Fifty consecutive first-time visitors with various 
skin disorders at age 0-4 years were examined by a dermatologist and classified as having 
eczema or non-eczema in accordance with the criteria of Hanifin and Rajka. Before the visit, 
the parents were asked to fill out a questionnaire including the question upon which the 
eczema definitions in the BAMSE follow-ups are based. The questionnaire-derived eczema 
diagnosis, when compared with the clinical diagnosis, displayed a sensitivity and specificity of 
92% and 100%, respectively.127 In study I and study IV, the definition of eczema at age 16 
years was based on symptoms of eczema reported by the adolescents (i.e. not by their 
parents). In contrast, the definition of eczema at age 16 years used in study II was based on 
parental-reported symptoms of eczema at age 16 years and/or doctor’s diagnosis since last 
follow-up. This definition was chosen to cover the period between follow-ups at age 12 and 
16 years. 
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Table 3 Definition of eczema used in studies I-IV based on parental report, unless 
otherwise stated. 
Variable Definition Study 
Eczema at age 1, 2, and 4 
years 
Dry skin and itchy skin rash for ≥two weeks on specific locations 
(face or arm/leg extension surfaces or arm/leg flexures or 
wrist/ankle flexures) over the last 12 months and/or doctor’s 
diagnosis of eczema since last follow-up. 
I, II, III, 
IV 
Eczema at age 8 years Dry skin and itchy skin rash for ≥two weeks on specific locations 
(face or arm/leg flexures or wrists/ankles or neck) over the last 
12 months and/or doctor’s diagnosis of eczema after 4 years of 
age up to 8 years of age. 
I, II, IV 
Eczema at age 12 years Dry skin and itchy skin rash on specific locations (arm/leg 
flexures or wrists/ankles or neck) over the last 12 months 
and/or doctor’s diagnosis of eczema after 10 years of age up to 
12 years of age. 
I, II, IV 
Eczema at age 16 years Dry skin and itchy skin rash on specific locations (arms/legs 
flexures or wrists/ankles or neck) over the last 12 months 
and/or doctor’s diagnosis of eczema after 12 years of age up to 
16 years of age. 
II 
Eczema at age 16 years Dry skin and itchy skin rash on specific locations (arm/leg 
flexures or wrists/ankles or neck) over the last 12 months. 
Reported by adolescent. 
I, IV 
Atopic eczema (AE) Eczema reported by adolescent in combination with any IgE 
sensitization, both at age 16 years. 
I 
Nonatopic eczema (non-
AE) 
Eczema reported by adolescent in combination with absence of 
any IgE sensitization, both at age 16 years. 
I 
Infantile eczema Eczema at age 1 and/or 2 years. II 
Preschool eczema (PSE) Eczema at age 1, 2, and/or 4 years. II, III, IV 
Eczema at school age Eczema at age 8, 12, and/or 16 years. II 
Eczema ever up to age 
16 years 
Eczema at age 1, 2, 4, 8, 12, and/or 16 years. II 
Transient eczema Eczema at 1, 2, and/or 4 years and no eczema at 8, 12, or 16 
years. 
II 
Eczema with onset at 
school age 
No eczema at 1, 2, or 4 years and eczema at 8, 12, and/or 16 
years. 
II 
Persistent eczema Eczema at 1, 2, and/or 4 years and eczema at 8, 12, and/or 16 
years. 
II 
Persistent PSE Eczema at age 1, 2, and 4 years. III, IV 
PSE with sleep 
disturbance 
Eczema (reported symptoms and/or doctor’s diagnosis) in 
combination with reported sleep disturbance due to itch at 
least once a week at 1, 2, and/or 4 years of age. 
II, III, IV 
Persistent eczema at 
school age 
Eczema at age 8, 12, and 16 years. IV 
Intermittent eczema at 
school age 
Eczema at one or two follow-ups at 8, 12 and/or 16 years. IV 
Complete remission at 
school age 
No eczema at age 8, 12, or 16 years. IV 
Remission at age 16 
years 
No eczema at age 16 years. IV 
Doctor’s diagnosis of 
infantile eczema and 
preschool eczema 
Doctor’s diagnosis of eczema at age 0-2 or 0-4 years, 
respectively, compared with children without doctor’s diagnosis 
regardless of reported symptom of eczema. 
II 
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Health outcomes other than eczema (I-IV) 
The definitions of asthma and rhinitis were also based on questionnaire data (Table 4). 
Parental reports were used in studies II, III and IV. In study I, adolescents reported the 
symptoms of asthma and rhinitis at age 16 years. 
While the BAMSE material primarily covers allergy-related diseases, the definitions of ADHD, 
depression/anxiety/phobia, epilepsy and migraine in study II were based on prescribed and 
dispensed medication for each particular disorder during school age (10-18 years). The drugs 
had to be registered as dispensed at least once between July 1 2005 and Dec 31 2013. 
 
Table 4 Definitions of health outcomes used in studies I-IV, based on parental report 
unless otherwise stated. 
Variable  Definition Study 
Asthma at 1 year of age At least 3 episodes of wheeze after age 3 months and up 
to 1 year of age in combination with treatment with 
inhaled glucocorticoids and/or sign of suspected 
hyperactivity without concurrent upper respiratory 
infection.  
II, III, 
IV 
Asthma at 2 years of age At least 3 episodes of wheeze after 1 year and up to 2 
years of age in combination with treatment with inhaled 
glucocorticoids and/or sign of suspected hyperactivity 
without concurrent upper respiratory infection.  
II, III, 
IV 
Asthma at 4, 8, 12, and 16 
years of age 
More than 3 episodes of wheeze in the last 12 months 
and/or at least 1 episode of wheeze in the last 12 months 
in combination with inhaled glucocorticoids occasionally 
or regularly. Reported by adolescent at 16 years. 
I, II, 
III, IV 
Preschool asthma Asthma at age 1, 2, and/or 4 years. III, IV 
Asthma ever up to 16 years 
of age 
Asthma at 1, 2, 4, 8, 12, and/or 16 years of age. II 
Rhinitis 
 
Symptoms from nose and/or eyes after exposure to 
furred pets or pollen. 
I, II, 
III, IV 
Rhinitis at 1 year of age Symptoms and/or doctor’s diagnosis at 0-1 year. II, III, 
IV 
Rhinitis at 2, 4, 8, and 16 
years of age 
Symptoms in the last 12 months and/or doctor’s 
diagnosis since previous follow-up. 
III, III, 
IV 
Rhinitis at 12 years of age Symptoms in the last 12 months and/or doctor’s 
diagnosis at age 10-12 years. 
II 
Rhinitis at 16 years of age Symptoms in the last 12 months Reported by adolescent. I 
Preschool rhinitis Rhinitis at age 1, 2, and/or 4 years. III, IV 
Rhinitis ever up to 16 years 
of age 
Rhinitis at 1, 2, 4, 8, 12, and/or 16 years of age. II 
ADHD medication at school 
age 
Dispensed psychostimulants (ATC-code N06A) at age 10-
18 years. 
II 
Antidepressants at school 
age 
Dispensed antidepressants (ATC-code N06B) at age 10-18 
years. 
II 
Anti-epileptics at school 
age 
Dispensed anti-epileptic drugs (ATC-code N03A) at age 
10-18 years. 
II 
Migraine drugs at school 
age 
Dispensed migraine drugs (ATC-code N02C) at age 10-18 
years. 
II 
  25 
 
Eczema severity (I) 
To evaluate eczema severity, a modified scale of BAMSE Eczema Severity Score (BESS) was 
used. BESS, scale 3-14, was developed and used in the 12-year follow-up,29 and is based on 
the answers to three questions. In study I, BESS was modified to BESS(3-12), scale 3-12, since 
one of the questions had fewer multiple choice answers in the 16-year follow-up than in the 
12-year follow-up (Figure 4). The adolescents in study I were classified as having mild (3-7), 
moderate (8-9) or severe eczema (10-12). 
BAMSE Eczema Severity Score (BESS(3-12)) 
  
Score 
Questionnaire, 
Multiple choice options 
Disease severity  
Has your sleep been disturbed by itching during 
the last 12 months? 
1 No 
  
2 Less often than once a week   
3 Once a week or more often 
Disease course  
For how long, in total, have you had eczema 
during the last 12 months? 
1 <1 month 
  
2 1-3 months   
3 4-6 months   
4 >6 months 
Extent of body surface involvement  
Where has the itchy rash been located the last 12 
months?a 
1 1 body site 
  
2 2 body sites   
3 3-4 body sites   
4 5-6 body sites   
5 >6 body sites 
Total score 3-12 
 
Figure 4 Description of BESS(3-12) constructed and used in study I. 
a The adolescents could choose between 14 different specified locations (scalp; face; ears; neck; trunk/back, 
stomach, shoulders; armpits; extensor surface of arms and legs; body folds of arms and legs; wrists/ankles; 
hands; buttocks; inside of the thighs; genital area/groin; feet). The number of body sites was categorized. 
IgE sensitization (I, III, IV) 
Analyses of serum IgE antibodies in blood collected at age 4, 8, and 16 years were performed. 
Airborne allergens were analyzed with Phadiatop® (dog, cat, horse, birch, timothy, house dust 
mite (Dermatophagoides pteronyssinus), mugwort, and mold (Cladosporium herbarum)), and 
food allergens with fx5® (hen’s egg, cow’s milk, cod, peanut, soy, and wheat), using the 
ImmunoCAP System (Thermo Fisher Scientific, Uppsala, Sweden). The results were expressed 
as positive (≥0.35 kUA/L) or negative (<0.35 kUA/L). To be classified as having IgE sensitization 
in a specific age, a child was required to be positive for Phadiatop and/or fx5 in that age. Sera 
with Phadiatop or fx5 results of ≥0.35 kUA/L were subsequently analyzed for IgE antibodies to 
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the airborne and food allergens listed above, and in addition to Dermatophagoides farinae 
(house dust mite) in the 16-year follow-up. IgE sensitization to a specific allergen was defined 
as IgE ≥0.35 kUA/L to that allergen. 
In study III, children with IgE sensitization were classified as having monosensitization, 
oligosensitization or polysensitization. Monosensitization was defined as an IgE level ≥0.35 
kUA/L to a single allergen, or positive for Phadiatop and/or fx5 without reaching ≥0.35 kUA/L 
to any of the allergens included in the mixes. Oligosensitization and polysensitization were 
defined as IgE ≥0.35 kUA/L to 2-3 allergens and IgE ≥0.35 kUA/L to ≥4 allergens, respectively. 
Filaggrin mutation (III, IV) 
DNA was extracted from blood collected at age 8 years (n=2,025), and 16 years (n=2,130). 
Genotyping was performed for the FLG mutations common in Sweden (2282del4, R501X, 
R2447X).128 Children with a mutation in any of the positions mentioned above were classified 
as having a FLG mutation. The genotyping in the 8-year follow-up was performed using 
TaqMan allelic discrimination for R501X and R2447X on the ABI Prism 7500 detection system 
(Applied Biosystems, CA, USA) and MALDI-TOF (matrix-assisted laser desorption/ionization-
time of flight; Sequenom GmbH, Hamburg, Germany) for 2282del4. TaqMan SNP Genotyping 
Assays for all three mutations were used in the 16-year follow-up (obtained from Applied 
Biosystems, CA, USA). The analysis successfully performed on blood from the 8-year follow-
up (n=1,940) was available for study III. In study IV, successful analyses from both the 8- and 
the 16-year follow-ups (n=2,748) were accessible. 
STATISTICAL METHODS 
All statistical calculations were performed with Stata statistical software (release 12.1; 
StataCorp, College Station, TX, USA). 
Confidence intervals (I, II, III, IV) 
Background characteristics were expressed as percentage of the total number of individuals 
observed (I, II, III, IV). To compare the study population with the original cohort, 95% CIs were 
calculated by applying one-sample t-tests with finite population correction (I, II, III).129 
Chi2-tests (I, II, III, IV) 
To compare two groups, 2-tests were used for dichotomous variables. P-values less than 
0.05 were considered statistically significant. 
Logistic regression (II, III, IV) 
Logistic regression was used in study II (to investigate the association between dispensed 
medication for ADHD, depression/anxiety/phobia, epilepsy, migraine and PSE), in study III (to 
evaluate the association between PSE and mono-/oligo-/polysensitization), and in study IV (to 
explore the association between exposures in the first 4 years of life and complete remission 
at school age). First, univariate analyses were performed. In study II, different potential 
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confounder models were tested. The final model was adjusted for factors included due to 
prior knowledge, and confounders that changed the OR by >10%. Potential significant effect 
modification was evaluated for the same covariates (II). 
Multivariate prognostic models (IV) 
Multivariate models were created in study IV to analyze the possibility for complete remission 
of PSE (IV). Factors were included if the crude univariate logistic regression was significant or 
if the factor was chosen to be included a priori,  based on literature. Backwards selection was 
performed, and factors with P >0.15 were excluded from the model. The factors that 
remained in the model were tested for effect modification, each factor pairwise with all other 
factors. The likelihood ratio test was used to compare the model with and without interaction 
terms and was considered significant if P <0.05. The correct classification rate was calculated 
as the number of correctly classified individuals divided by the total number of individuals. 
Generalized estimated equations (III) 
To study the longitudinal association between IgE sensitization (any, food and aeroallergens) 
at 4, 8, and 16 years and PSE, and/or FLG mutations, logistic regression models using 
generalized estimating equations (GEEs) with an unstructured correlation matrix to account 
for the correlation between repeated outcomes were used (IV). Unstructured correlation was 
used due to the longitudinal design and the unequal spacing to the follow-up point in time. 
Potential effect modifiers of the association between PSE and FLG mutation, respectively, and 
IgE sensitization, were investigated using logistic regression for each covariate separately. To 
analyze if associations between PSE and IgE sensitization outcomes varied with age, an 
interaction term was added to each model. The models were adjusted for sex and parental 
allergy, and additional potential confounders were included if the univariate analysis changed 
the OR more than 10%. 
Cluster analysis (III) 
In study III, cluster analysis was performed (to explore patterns of specific IgE sensitization). 
The k-means method with Euclidean distance between the observations was used, since this 
gave the most stable clusters compared with other methods tested (Jaccard and matching). 
This analysis was performed separately at age 4, 8, and 16 years. Moreover, 2-, 3-, 4-, and 5-
cluster models were tested, and the clusters that maximized the Calinski-Harabasz pseudo-F 
were selected.130 
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4 RESULTS 
ECZEMA IN ADOLESCENCE (I) 
The 3,108 adolescents with data available for the diagnosing of eczema in adolescence 
constituted the study population and were comparable with the original cohort regarding 
background factors (I). 
 
Table 5 Background characteristics of children in the original cohort and study population 
in study I. 
  Original cohort (n=4,089)  Study population (n=3,108) 
Background factors  n %  n % 95% CI 
Male  2,065/4,089 50.5  1,529/3,108 49.2 (48.3-50.1) 
Low socioeconomic 
statusa 
 695/4,072 17.1  490/3,097 15.8 (15.2-16.5) 
Exclusive 
breastfeeding ≥4 
months 
 3,116/3,919 79.5  2,438/3,038 80.3 (79.6-80.9) 
Parental allergyb  1,746/4,045 43.2  1,368/3,081 44.4 (43.5-45.3) 
Any parent smoking 
at baselinec  
 855/4,067 21.0  631/3,090 20.4 (19.7-21.1) 
Any parent born 
outside Scandinaviad 
 543/3,398 16.0  453/2,941 15.4 (14.9-15.9) 
  Mean (range) SD  Mean (range) SD  
Age of mother (years)  30.7 (16-46) 4.5  30.8 (16-46) 4.5 (30.7-30.9) 
Gestational age 
(weeks) 
 39.8 (25-44) 2.0  39.8 (25-44) 2.0 (39.8-39.8) 
Confidence intervals created by applying finite population correction factor. Statistically significant 
differences in bold. 
aBoth parents were blue-collar workers, or one parent blue collar worker and the other parent was a 
student, housewife, on disability pension, or unemployed. 
bMother and/or father with asthma and/or hay fever and/or eczema at baseline. 
cAt least one cigarette per day. 
dEither parent not born in Sweden, Denmark, Norway or Finland. 
 
Epidemiology (I) 
The 12-month prevalence of eczema in adolescence was 9.6% (297 of 3,108). Eczema was 
significantly more common among girls (197 of 1,579 [12.5%]) than among boys (100 of 1,529 
[6.5%]). The 12-month prevalence of asthma and rhinitis was 7.6% and 27.1%, respectively. 
Of the adolescents who provided blood (n=2,529), 45.9% showed some IgE sensitization. 
Allergy-related diseases were significantly more common (P <0.001) among children with 
eczema than children without eczema (Figure 5).  
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Figure 5 Prevalence of allergy-related comorbidities among adolescents with and without 
eczema at age 16 years. All comorbidities were significantly more common among 
adolescents with eczema (P <0.001).  
AE vs. non-AE 
Data on IgE sensitization was available for 82.8% (n=246) of the adolescents with eczema. Of 
these, 59.3% had AE (n=146) and 40.7% had non-AE (n=100). AE was significantly more 
frequent among girls than boys (7.1% vs. 4.3%, P=0.003). Similarly, non-AE was more common 
in girls than boys (5.8% vs. 2.0%, P <0.001). 
Age at onset of eczema (I) 
Onset in the first two years of life was prevalent among adolescents with eczema (48.8%). 
Onset after age 12 years (25.6%) was also common. Onset after age 12 years was more 
common among girls (P=0.016), while onset in the first year of life was more common among 
boys (P <0.001). There were no other significant differences between sexes regarding age of 
onset. The adolescents with onset after age 12 (n=76) were compared with adolescents with 
onset ≤12 years (n=221) regarding reported symptoms of contact dermatitis, to investigate if 
contact dermatitis misclassified as eczema could explain the large proportion of onset after 
age 12 years. There were no significant differences between the groups in reported itchy rash 
or eczema after contact with metal, hair dye, make-up or personal hygiene products, or latex 
or rubber. 
AE vs. non-AE 
Age at onset before age 2 years was significantly more common among adolescents with AE 
than among adolescents with non-AE (61.6% vs. 30.0%, P<0.001). This difference was still 
significant when stratifying by sex. Furthermore, onset at age 12 years or later were 
significantly more common among adolescents with non-AE than AE (48.0% vs. 22.6%, 
P<0.001), and a comparable pattern was seen when stratified for sex (Table 6).  
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Table 6 Age at onset among adolescents with eczema based on when eczema was 
reported (by adolescent or parent) the first time in the BAMSE cohort. 
  AE (n=146)  non-AE (n=100) P-value 
Age at onset (years)  n %  n %  
Onset before age 1  61 41.8  13 13.0 <0.001 
Onset between age 1 and age 2  29 19.9  17 17.0 0.572 
Onset between age 2 and age 4  13 8.9  15 15.0 0.139 
Onset between age 4 and age 8  10 6.8  7 7.0 0.963 
Onset between age 8 and age 12  10 6.8  8 8.0 0.734 
Onset at age 16  23 15.8  40 40.0 <0.001 
Internal missing data ranged between 0 and 6.0%. Individuals with missing data were classified as having no 
disease for that particular follow-up. Significant differences in bold. 
 
Severity of eczema in adolescence (I) 
Based on BESS(3-12), adolescents with eczema were classified as having mild eczema (72.7%), 
moderate eczema (16.8%) or severe eczema (10.4%). 
AE vs. non-AE 
Severe eczema was more common in adolescents with AE than in those with non-AE (Figure 
6). 
 
Figure 6 AE and non-AE in relation to eczema severity according to BESS(3-12) at age 16 years 
(n=246). 
Seasonal variation of eczema in adolescence (I) 
Eczema was more common in winter than in other seasons (Figure 7). There were no major 
differences in seasonal variation between AE and non-AE or between sexes. 
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Figure 7 Reported seasonal prevalence of eczema among all adolescents with eczema at age 
16 years (n=280). There were 19 adolescents with no data on seasonality. 
 
Location of eczema (I) 
Those adolescents who had eczema during the preceding year reported where the eczema 
had been located. The majority had eczema in 3 locations and only a few reported more than 
10 locations. Flexural body areas were by far the most frequently affected (73.4%), Figure 8. 
More boys than girls reported eczema on extensor surfaces of extremities (47.0% vs. 34.5%, 
P=0.037). There were no other significant differences between sexes. 
 
 
Figure 8 Proportions of adolescents with reported eczema on different body sites within the 
last year. Each participant could choose between 14 locations, and the adolescents reported 
a mean of 3.5 (range 1-14) locations each (n=297). 
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AE vs. non-AE 
Eczema located on the ears was more common among adolescents with AE than among those 
with non-AE (11.0% vs. 3.0%, P=0.022). Adolescents with AE reported eczema on the face and 
on the inside of the thighs somewhat more often than adolescents with non-AE, but this 
difference was not significant. Altogether, there was no major difference in location of 
eczema between adolescents with AE and those with non-AE. 
Eczema history among adolescents with eczema (I) 
Adolescents with eczema at age 16 years, who had reported eczema in all previous follow-
ups in the BAMSE cohort, were classified as having chronic eczema. Chronic eczema affected 
almost 11% (32 of 297) of the adolescents with eczema and was more common among boys 
than girls (17.0% vs. 7.6%, P=0.014). 
AE vs. non-AE 
When comparing adolescents with AE and non-AE at age 16 years, those with AE had 
significantly higher prevalence of eczema in all preceding follow-ups (at age 1, 2, 4, 8, and 12 
years). One-third (32.9%) of adolescents with AE had reported eczema in four or five of the 
five preceding questionnaires compared with only 13.0% of the adolescents with non-AE. In 
contrast, 60.0% of adolescents with non-AE had reported eczema only at age 16 years or in 
one preceding questionnaire, twice as many as adolescents with AE (30.8%). Figure 9 shows 
history of eczema from birth to adolescence and illustrates the differences between 
adolescents with AE and non-AE.  
Figure 9:A Eczema history among adolescents with AE. For details, see Figure 9:B. 
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Figure 9:B Eczema history among adolescents with non-AE. Each row contains 100 squares, 
and each square represent 1% of the adolescents. The course of each percentage can be 
traced vertically, from bottom to top. Filled boxes represent children with eczema at that age. 
The different colors illustrate the number of preceding follow-ups (one to five) in which 
eczema was reported; green for chronic eczema (eczema at five of five follow-ups), red for 
four of five, blue for three of five, orange for two of five and purple for one of five.  Yellow 
color represent adolescents who reported eczema for the first time at the 16-year follow-up. 
Filaggrin mutation in relation to eczema in adolescence (additional data) 
Data on FLG mutation was available for 2,585 adolescents included in study I, and of them 
6.9% (n=178) had a FLG mutation. Adolescents with eczema more often had a FLG mutation 
than those without eczema (13.0% vs. 6.2%, P <0.001). The likelihood of having a FLG 
mutation did not differ between adolescents with AE or non-AE (14.5% vs. 12.0%, P=0.581). 
CONSEQUENCES OF PRESCHOOL ECZEMA LATER IN CHILDHOOD AND 
ADOLESCENCE (II, III) 
In studies II, III and IV, different aspects and consequences of PSE were evaluated. The 
prevalence of PSE varied with the different study populations and ranged between 32.7% and 
34.6%. The 12-month prevalence at age 1, 2, and 4 years was 15.1% (594 of 3,329), 19.0% 
(703 of 3,839) and 20.7% (769 of 3,721) , respectively (additional data). 
IgE sensitization (III) 
A history of PSE was associated with IgE sensitization from age 4 to 16 years (overall adjOR 
2.39, 95% CI: 2.00-2.63). A similar result was found when analyzing IgE sensitization to food 
(adjOR 2.05, 95% CI: 1.74-2.42) and aeroallergens (adjOR 2.51, 95% CI:2.18-2.92) separately. 
The highest point estimate was the association between PSE and aeroallergens at age 4 years 
(Figure 10). 
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Figure 10 Association between PSE and IgE sensitization at age 4, 8, and 16 years. Children 
with data on PSE and who provided blood at least once were included (n=3,201). A logistic 
regression model with GEE adjusted for sex and parental allergy was used. 
 
Children with PSE and sleep disturbance (here as a marker for more severe PSE) had higher 
point estimates than all children with PSE and those with persistent PSE had significantly 
higher point estimates (Table 7). 
 
Table 7 IgE sensitization at age 4, 8, and 16 years in relation to preschool eczema (PSE), 
severe PSE, persistent PSE and PSE in combination with FLG mutation. 
 
PSE (n=1107) Severe PSEb (n=381) Persistent PSEc 
(n=214) 
PSE and FLG 
mutationd (n=67)  
adjORe 95% CI adjORe 95% CI adjORe 95% CI adjORe 95% CI 
Any IgE 
sensitizationa 
        
4 2.55 2.12-3.06 3.87 3.01-4.98 6.07 4.40-8.37 2.74 1.53-4.88 
8 2.20 1.85-2.60 3.08 2.41-3.94 5.04 3.62-7.02 2.06 1.24-3.43 
16 2.21 1.87-2.61 3.12 2.39-4.06 4.99 3.41-7.29 2.52 1.44-4.42 
Foods 
        
4 2.10 1.70-2.59 2.96 2.23-3.91 4.34 3.11-6.06 2.30 1.20-4.40 
8 2.04 1.67-2.49 3.05 2.33-3.98 4.77 3.45-6.60 2.80 1.64-4.79 
16 2.01 1.59-2.54 3.00 2.20-4.08 5.30 3.71-7.56 2.56 1.32-4.95 
Airborne 
        
4 3.37 2.71-4.19 5.54 4.19-7.34 9.28 6.64-12.97 3.52 1.84-6.72 
8 2.49 2.08-2.99 3.47 2.69-4.48 5.90 4.27-8.16 2.02 1.18-3.46 
16 2.26 1.91-2.68 3.33 2.56-4.33 5.00 3.45-7.25 2.74 1.56-4.82 
aChildren with the result ≥0.35 kUA/L were classified as having IgE sensitization, bChildren with sleep 
disturbance in combination with eczema at 1, 2, and/or 4 years of age. Children with PSE without sleep 
disturbance and missing data at one or two ages were excluded, children without PSE (n=2,094) were the 
reference, cChildren with eczema at 1, 2, and 4 years of age. Children without PSE (n=2,094) were the 
reference, dChildren without PSE and FLG mutation (n=1,157) were the reference, eLogistic regression model 
using generalized estimating equations (GEEs), adjusted for sex and heredity. Effect modification was tested 
for sex, heredity, breastfeeding, parental smoking during infancy, mother’s age, socio-economy and filaggrin 
mutation. 
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In addition, PSE was associated with incident IgE sensitization at age 8 years (adjOR 1.44, 
95% CI: 1.08-1.91) and age 16 years (adjOR 1.48, 95% CI: 1.08-2.03). FLG mutation was not 
a significant effect modifier of the effect of PSE on IgE sensitization, and adjustment for FLG 
mutation did not change the ORs. Preschool asthma and preschool rhinitis were both 
significant effect modifiers of the effect of PSE on IgE sensitization. Therefore, children 
without asthma and rhinitis before age 4 were analyzed separately. The association 
between PSE and IgE sensitization up to age 16 years was still significant (overall adjOR 1.85, 
95% CI: 1.57-2.19). 
Preschool eczema and patterns of IgE sensitization 
As a second step, children with any IgE sensitization were selected at each age (4, 8, and 16 
years) and analyzed to explore if PSE was associated with specific patterns of IgE sensitization. 
Sensitized children with a history of PSE displayed a pattern of polysensitization in all ages. 
Sensitized children with no history of PSE had a pattern dominated by monosensitization 
(Figure 11).  
Figure 11 Proportions of mono-, oligo-, and 
polysensitization among IgE-sensitized 
children in the BAMSE cohort with and 
without PSE at age 4, 8, and 16 years. 
 
Furthermore, sensitized children with PSE 
demonstrated a higher prevalence of IgE 
sensitization to almost all allergens than 
sensitized children without PSE (Figure 12). 
To analyze further, a data-driven approach 
was applied. Cluster analysis including 
children with any sensitization at each 
respective age (4 years, 8 years and 16 
years) was used. In the analyses, IgE 
sensitization to each of the 14 analyzed 
specific allergens was included as a 
dichotomous variable (positive or 
negative). The children were stratified for 
PSE to analyze whether children with PSE 
would display a different pattern than 
children without PSE. The 2-cluster model 
was the most stable model among children 
with PSE. Among sensitized children without PSE, no stable clusters were found. Therefore, 
the sensitization patterns between sensitized children with and without PSE could not be 
compared. Instead, a cluster analysis including all children with IgE sensitization at 4, 8, and 
 36 
16 years was performed. Altogether, the 2-cluster model was the most stable with the highest 
Calinski-Harabsz pseudo-F value at all ages. One cluster was larger and characterized by 
mono- and oligosensitization. The other, smaller cluster was characterized by 
polysensitization. PSE was significantly more frequent in the cluster with polysensitization at 
all ages (Table 8). The data-driven approach did not provide any additional patterns of IgE 
sensitization associated with PSE. 
 
Table 8 Cluster analysis on IgE sensitization at 4, 8, and 16 years. Descriptive analysis in 
2-cluster model among children with any IgE sensitization at each respective age. 
 Cluster 1 Cluster 2 All P-value Missing 
2-cluster model at 4 years  n=506 n=89 n=595 
  
Preschool eczema 47.0% 80.9% 52.1% <0.001 0 
FLG mutation 7.8% 8.3% 7.9% 0.89 215 
Male sex 52.8% 68.5% 55.1% 0.006 0 
Parental allergya 49.4% 54.0% 50.1% 0.43 6 
Parental smokingb 21.0% 32.2% 22.6% 0.021 3 
Exclusive breastfeeding ≥4 
months 
78.0% 78.4% 78.0% 0.93 3 
Monosenstization 58.9% 0.0% 50.1% <0.001 0 
Oligosensitization 35.6% 0.0% 30.3% <0.001 0 
Polysensitization 5.5% 100.0% 19.7% <0.001 0 
2-cluster model at 8 years n=564 n=241 n=805   
Preschool eczema 41.1% 66.0% 48.6% <0.001 0 
FLG mutation 6.7% 9.6% 7.5% 0.20 141 
Male sex 52.5% 57.3% 53.9% 0.21 0 
Parental allergya 48.0% 61.8% 52.2% <0.001 4 
Parental smokingb 20.8% 20.2% 20.6% 0.84 5 
Exclusive breastfeeding ≥4 
months 
78.6% 80.3% 79.2% 0.59 4 
Monosenstization 55.1% 0.0% 38.6% <0.001 0 
Oligosensitization 39.7% 0.0% 27.8% <0.001 0 
Polysensitization 5.1% 100.0% 33.5% <0.001 0 
2-cluster model at 16 years n=663 n=471 n=1134   
Preschool eczema 38.8% 54.6% 44.2% <0.001 0 
FLG mutation 8.4% 6.1% 7.4% 0.22 389 
Male sex 53.2% 54.8% 53.9% 0.61 0 
Parental allergya 48.0% 58.2% 52.2% 0.001 11 
Parental smokingb 21.1% 18.3% 19.9% 0.20 6 
Exclusive breastfeeding ≥4 
months 
79.2% 77.9% 78.7% 0.17 9 
Monosenstization 61.4% 0.0% 35.9% <0.001 0 
Oligosensitization 35.6% 14.0% 26.6% <0.001 0 
Polysensitization 3.0% 86.0% 37.5% <0.001 0 
aMother and/or father with doctor’s diagnosis of asthma and/or hay fever and/or eczema (contact allergy 
among parents is excluded) at baseline, bAny of the parents smoked at least one cigarette per day at child´s 
birth. Significant differences in bold. 
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Figure 12 Pattern of IgE sensitization at age 4 (A), 8 (B), and 16 (C) years stratified by PSE. Bars 
represent the proportions of children with specific IgE ≥0.35 kUA/L for each allergen. Children 
with any IgE sensitization and complete data on PSE and specific IgE measurement at each 
age were included. *Significant differences.  
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ADHD (II) 
There were minor differences in background characteristics between the study population of 
study II (n=3,606) and the original cohort (n=4,089). Assuming a prevalence of ADHD 
medication of 5% among children without PSE and a two-sided significance level of 0.05, the 
study II had 80% power to detect an OR of 1.51. 
 
Table 9 Background characteristics for children in the original cohort, the study population 
and the subpopulation (II). 
Background factors  Original cohort  Study population 
(n=3,606) 
 Subpopulationa 
(n=2,736) 
  n=4,089 %  % (95% CI)  % (95% CI) 
Male  2,065/4,089 50.5  50.6 (50.1-51.2)  49.9 (48.8-50.9) 
Low socioeconomic statusb  695/4,072 17.1  16.4 (16.0-16.9)  14.8 (14.0-15.6) 
Exclusive breastfeeding ≥4 
months 
 
3,116/3,919 79.5  79.9 (79.6-80.3)  81.1 (80.3-81.9) 
Parental allergyc  1,746/4,045 43.2  43.6 (43.1-44.2)  45.0 (43.9-46.1) 
Any parent smoking at 
baselined 
 
855/4,067 21.0  20.5 (20.0-20.9)  19.7 (18.9-20.6) 
Any parent born outside 
Scandinaviae 
 
543/3,398 16.0  15.2 (14.9-15.5)  14.3 (13.8-14.9) 
Young mother (<25 y)  319/4,088 7.8  7.4 (7.1-7.7)  6.5 (6.0-7.0) 
ADHD medication at school 
agef 
 
184/4,089 4.5  4.5 (4.3-4.7)  3.7 (3.3-4.1) 
Confidence intervals created by applying one-sample t-tests with a finite population correction factor. 
Statistically significant differences in bold, aIncluding children who participated in all follow-ups up to age 16 
years, bBoth parents were blue-collar workers, or one parent blue-collar worker and the other parent was a 
student, housewife, on disability pension, or unemployed, cMother and/or father with asthma and/or hay 
fever and/or eczema at baseline, dAt least one cigarette per day 
eEither parent not born in Sweden, Denmark, Norway or Finland, fEver use of ADHD medication at age 10-18 
years of age (range 8.6-19.9). 
 
The prevalence of ADHD medication at school age was 4.5% (n=162) in the study population, 
and 3.7% (n=101) in the subpopulation of children who participated in all follow-ups. The 
group that had used ADHD medication was characterized by male sex (69.8% vs. 49.7%, P 
<0.001), young mother (15.4% vs. 7.0%, P<0.001), parental smoking (28.8% vs. 20.1%, P= 
0.008), low socio-economy (28.0% vs. 15.9%, P <0.001), and exclusive breastfeeding less than 
4 months (27.2% vs. 19.7%, P=0.02). 
The prevalence of PSE was 32.7%, and 25.2% had eczema before age 2 years (infantile 
eczema). In the subpopulation, 41.2% (n=1,126) had eczema ever, up to age 16 years. Of 
these, 434 had transient eczema, 440 had persistent eczema and 252 had eczema with onset 
during school age. 
Eczema in relation to ADHD medication at school age 
PSE was not associated with ADHD medication, either in the crude analysis (OR 1.16, 95% CI: 
0.83-1.61) or the analysis adjusted for sex, exclusive breastfeeding ≥4 months, parental 
smoking, and socioeconomy (adjOR 1.12, 95% CI: 0.80-1.56). Furthermore, PSE with sleep 
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disturbance (proxy for severe PSE) was not associated with ADHD medication (adjOR 1.29, 
95% CI 0.80-2.08), neither was reported doctor’s diagnosis of PSE (adjOR 1.07, 95% CI 0.73-
1.55). In addition (not included in study II), persistent PSE tended to be associated with ADHD 
medication, but not significantly (adjOR 1.69, 95% CI: 0.99-2.89). Stratification by sex did not 
show any differences between boys and girls. 
Similarly, infantile eczema (adjOR 1.31, 95% CI: 0.93-1.86), reported doctor’s diagnosis of 
infantile eczema (adjOR1.14, 95% CI: 0.77-1.70), eczema at school age (adjOR 1.16, 95% CI: 
0.74-1.83), or eczema ever up to age 16 years (Table 10) were not associated with ADHD 
medication. Altogether, there was no significant association between PSE or eczema at other 
ages up to age 16 years, and ADHD medication at school age. 
 
Table 10 Association between eczema ever up to 16 years, and ADHD medication (any 
time at 10-18 years of age). 
Eczema ever up to 16a ADHD medication at school age 
 Total  Cases  Crude OR  Adjusted ORb,c 
 n=2,736  n=101 %  OR (95% CI)  OR (95% CI) 
No eczema (ref) 1,610  57 3.5  1  1 
Eczema 1,126  44 3.9  1.11 (0.74-1.65)  1.09 (0.72-1.64) 
 Transient eczemad 434  15 3.5  0.98 (0.55-1.74)  0.99 (0.55-1.78) 
 Eczema with onset 
at school agee 
252  7 2.8  0.78 (0.35-1.73)  0.87 (0.39-1.93) 
 Persistent eczemaf 440  22 5.0  1.43 (0.87-2.37)  1.28 (0.75-2.16) 
The analysis was performed among children in the BAMSE cohort who participated in all follow-ups, 
n=2,736, aEczema at 1, 2, 4, 8, 12, and/or 16y, bAdjusted for background variables; sex, breastfeeding, 
parental smoking, socio-economy, cThere were 0-15 missing values among background variables, n=2,714 
dEczema at 1, 2, and/or 4y and no eczema at 8, 12, or 16y, eEczema at 8, 12, and/or 16y and no eczema at 1, 
2 or 4y, fEczema at 1, 2, and/or 4y and eczema at 8, 12, and/or 16y. 
 
Depression/anxiety/phobia, migraine, epilepsy (II) 
A history of PSE was not associated with use of antidepressants, antiepileptic drugs, or 
migraine drugs at school age (Table 11), neither was PSE with sleep disturbance (severe PSE). 
 
Table 11 Association between preschool eczema and use of drugs for CNS-associated 
disorders at school age (10-18 years of age). 
Prescribed 
medication 
Children with 
eczema n=1,178 
 Children without 
eczema n=2,428 
  
Crude OR 
 
Adjusted ORa,b 
 n %  n %  OR (95% CI) OR (95% CI) 
Antidepressants 69 5.9  168 6.9  0.84 (0.63-1.12) 0.83 (0.62-1.11) 
Migraine drugs 27 2.3  48 2.0  1.16 (0.72-1.87) 1.05 (0.64-1.72) 
Antiepileptics 20 1.7  38 1.6  1.09 (0.63-1.88) 1.05 (0.60-1.84) 
Children in the BAMSE cohort whose parents participated in the follow-up and provided information on 
eczema at 1, 2 and 4, years of age, constituted the study population, n=3,606. 
aAdjusted for background variables; sex, exclusive breastfeeding <4 months, parental smoking, socio-
economy. 
bThere were 0-19 missing values among background variables, n=3,573. 
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NATURAL COURSE OF PRESCHOOL ECZEMA UP TO AGE 16 YEARS (IV) 
The prevalence of PSE among children in the BAMSE cohort was 34.4% (1,272 of 3,700). Of 
these, the 889 children who participated in all follow-ups up to age 16 years constituted the 
study population in study IV. Onset before age 1 year was most common (46.1%), followed 
by onset between age 1 year and 2 years (31.7%), and onset between 2 years and 4 years 
(22.2%). Moreover, 18.7% (n=166) of children with PSE had persistent PSE (eczema at age 1, 
2, and 4 years) and 33.2% (n=295) had PSE with sleep disturbance. 
At school age, half of the children with PSE (50.8%) were in complete remission. Persistent 
eczema at school age was found among 8.2%, and 40.9% had eczema in one or two follow-
ups (intermittent eczema at school age), Figure 13. Remission at age 16 years (no eczema at 
16) was reported by 82.2% of the adolescents with a history of PSE. 
 
 
Figure 13 The course of eczema up to age 16 years among children with preschool eczema 
(n=889) in the BAMSE cohort. 
 
Complete remission at school age was most common among children with onset before age 
1 year (those with persistent eczema excluded), Table 12. 
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Table 12 The course of different phenotypes of preschool eczemaa up to age 16 years 
(n=889). 
 Complete remissionb Intermittent eczema 
at school agec 
Persistent eczema 
at school aged 
PSE n % 95% CI n % 95% CI n % 95% CI 
All (n=889) 452 50.8 47.654.1 364 40.9 37.744.2 73 8.2 6.410.0 
Persistente  39 23.5 17.030.0 95 57.2 49.664.8 32 19.3 13.225.3 
Onset before age 1f 162 66.4 60.472.4 76 31.1 25.337.0 6 2.5 0.54.4 
Onset between age 1 
and 2g 
147 52.1 46.358.0 114 40.4 34.746.2 21 7.4 4.410.5 
Onset between age 2 
and 4h 
104 52.8 45.859.8 79 40.1 33.247.0 14 7.1 3.510.7 
aPreschool eczema (PSE): Eczema at 1, 2, and/or 4 years (n=889). 
bComplete remission: No eczema at 8, 12, and 16 years. 
cIntermittent eczema: Eczema at one or two follow-ups at 8, 12, and/or 16 years. 
dPersistent eczema: Eczema at 8, 12, and 16 years. 
ePersistent PSE: Eczema at 1, 2, and 4 years (n=166). 
fChildren with onset during the first year of life; children with persistent PSE were excluded (n=244). 
gOnset between age 1 year and age 2 years (n=282). 
hOnset between age 2 years and age 4 years (n=197). 
 
 
FACTORS OF IMPORTANCE FOR REMISSION OF PRESCHOOL ECZEMA (IV) 
Exposures in the first 4 years of life of possible importance for remission of PSE were explored 
in relation to complete remission of PSE. Persistent PSE, PSE with sleep disturbance, FLG 
mutation, parental smoking, parental allergy, IgE sensitization to food and/or aeroallergens, 
and preschool rhinitis were all inversely associated with complete remission at school age. In 
contrast, overweight at age 4 years and exclusive breastfeeding ≥4 months were positively 
associated with complete remission (Table 13).  
 42 
Table 13 Association between risk and protective factors in the first 4 years of life and 
complete remission of preschool eczema (PSE) at age 8, 12, and 16 years.  
Total  Complete remission of PSE 
Exposure n %  n % OR 95% CI 
All children with PSEa 889 100.0  452 50.8   
Questionnaire data        
Male 434/889 48.8  234 53.9 1.27 0.981.66 
Low birth weight 24/889 2.7  13 54.2 1.15 0.512.59 
Preterm birth 35/889 3.9  19 54.3 1.15 0.592.28 
Young mother 59/889 6.6  31 52.5 1.08 0.631.83 
Parent born outside of 
Scandinavia 
132/884 14.9  63 47.7 0.86 0.591.25 
Older sibling in household 425/889 47.8  203 47.8 0.79 0.611.03 
Low socio-economy 139/886 15.7  72 51.8 1.04 0.731.50 
Parental smoking 184/881 20.9  81 44.0 0.70 0.510.97 
Exclusive breastfeeding ≥4 
months 
707/878 80.5  371 52.5 1.41 1.011.98 
Parental allergy 478/885 54.0  225 47.1 0.73 0.560.95 
Persistent PSE 166/889 18.7  39 23.5 0.23 0.160.34 
PSE with sleep disturbanceb 295/889 33.2  112 38.0 0.46 0.340.61 
Preschool asthma 141/862 16.4  67 47.5 0.84 0.591.21 
Preschool rhinitis 204/842 24.2  85 41.7 0.63 0.460.87 
Data based on clinical and laboratory 
examinations 
      
FLG mutationc 78/764 10.2  30 38.5 0.58 0.360.93 
IgE sensitization to 
aeroallergens 
188/670 28.1  77 41.0 0.62 0.440.87 
IgE sensitization to food 
allergens 
157/671 23.4  60 38.2 0.55 0.380.79 
Overweight at age 4 years 119/763 15.6  71 59.7 1.53 1.032.27 
Odds ratio (OR) and 95% confidence intervals (CI) calculated with crude univariate logistic regression. 
Significant differences in bold. aPreschool eczema (PSE); eczema at age 1, 2, and/or 4 years, bEczema and sleep 
disturbance due to itch at age 1, 2, and/or 4 years, cChildren with a mutation in any of the positions 2282del4, 
R501X or R2447X were classified as having a filaggrin (FLG) mutation. 
 
Significant factors from the univariate analyses, and factors of possible importance based on 
literature (asthma, sex, socio-economy, and older sibling in household) were included in a 
multivariate prognostic model. 
First, factors based on questionnaire data were analyzed and significant factors are shown in 
Table 14, Prognostic model 1. The following factors were excluded from Prognostic model 1: 
preschool asthma (P=0.79), low socio-economy (P=0.52), preschool rhinitis (P=0.43), and 
older sibling in household (P=0.20). To analyze if the association between exclusive 
breastfeeding ≥4 months and complete remission was affected by disease modification of 
exposure, we restricted the analysis by excluding children with their first symptom of eczema 
during exclusive breastfeeding in the first 4 months of life. The multivariate model did not 
change following this exclusion, and the point estimates in the full model and the restricted 
model were comparable. 
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In the same manner, Prognostic model 2 including children with data on IgE sensitization and 
FLG mutation was created. All factors explored in Prognostic model 1 were included, as was 
additional data from the clinical and laboratory examination. From this new multivariate 
model, the following factors were excluded: preschool asthma (P=0.92), overweight at age 4 
years (P=0.78), low socio-economy (P=0.73), preschool rhinitis (P=0.57), IgE sensitization to 
aeroallergens at age 4 years (P=0.81), older sibling in household (P=0.47) exclusive 
breastfeeding ≥4 months (P=0.16) and parental allergy (P=0.19). The point estimates in 
Prognostic model 2 were comparable with and without inclusion of exclusive breastfeeding 
≥4 months and parental allergy. 
 
Table 14 Multivariate model of prognostic factors for complete remission of preschool 
eczema (PSE).  
Prognostic model 1: Questionnaire data (n=866)  
OR 95% CI P value 
Persistent PSE 0.27 0.180.41 <0.001 
PSE with sleep disturbance 0.59 0.430.81 0.001 
Male 1.37 1.031.82 0.029 
Parental allergy 0.73 0.550.96 0.026 
Parental smoking 0.70 0.500.99 0.045 
Exclusive breastfeeding ≥4 months  1.44 1.012.05 0.046 
Prognostic model 2: Data based on questionnaires and laboratory examinations (n=604) 
 OR 95% CI P value 
Persistent PSE 0.24 0.150.40 <0.001 
PSE with sleep disturbance 0.61 0.420.90 0.012 
Filaggrin (FLG) mutation 0.47 0.260.85 0.012 
Male 1.50 1.062.12 0.021 
Parental smoking 0.66 0.421.02 0.063 
IgE sensitization to food allergens 0.69 0.451.05 0.086 
Models created with multivariate logistic regression. Factors with a P value >0.15 were excluded, backwards 
selection. 
 
The developed Prognostic model 1 exhibited sensitivity of 78%, specificity of 49%, positive 
predictive value (PPV) of 61% and negative predictive value (NPV) of 68%. The efficacy of the 
prognostic model (correct classification rate) was 63%. The corresponding results for 
Prognostic model 2 were: sensitivity 75%, specificity 54%, PPV 62%, NPV 69%, and efficacy 
65%. 
Absolute risk for complete remission 
Persistent PSE, PSE with sleep disturbance, female sex, parental allergy, parental smoking, 
exclusive breastfeeding <4 months and FLG mutation were all significantly inversely 
associated with complete remission of PSE, based on Prognostic model 1 and/or Prognostic 
model 2. In the study population (IV), none of the participants had all seven risk factors. The 
probability for complete remission was 68% among children with 0-1 factors (n=273), 49% 
among children with 2-3 factors (n=475), and 25% among children with 4-6 factors (n=141). 
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Boys without any of the above listed factors had a probability of 71% to be in complete 
remission at school age, and the corresponding probability for girls was 60%. 
CONSEQUENCES OF FILAGGRIN MUTATION (III, IV) 
The FLG analyses performed on blood collected at the 8-year follow-up had a success rate of 
95.8% (1,940 of 2,025), and were used in study III. Of these, 1,890 children were included in 
the study population (III). Additional analyses of blood collected at the 16-year follow-up were 
performed successfully in 99.8% of samples (2,126 of 2,130). In study IV, results from both 
the 8- and the 16-year follow-ups were used and the combined success rate was 98.5% (764 
of 776) in the study population (IV). 
FLG mutation in relation to preschool eczema (III, IV) 
Among the 1,890 children with data on FLG mutation in study III, 7.3% (n=137) had any FLG 
mutation. Approximately half of them (48.9%) had PSE. FLG mutation was more common 
among children with PSE than children without PSE (10.1% vs. 5.7%, P <0.001).  
When performing study IV, data on FLG mutation was available for 2,748 in the BAMSE 
cohort. In total, 7.0% (n=191) had any FLG mutation. Similarly, the prevalence of FLG mutation 
was 7.0% (187 of 2,656) among children with data on PSE. As in study III, FLG mutation was 
more common among children with PSE than children without PSE (10.2% vs. 5.4%, P <0.001). 
Children with FLG mutation more often developed PSE than children without FLG mutation 
(49.2% vs. 33.0%, P <0.001) (additional data). 
FLG mutation in relation to IgE sensitization (III) 
Having a FLG mutation was not associated with IgE sensitization at age 4, 8, or 16 years (Figure 
14). However, when analyzing each allergen separately, FLG mutation was associated with IgE 
sensitization to peanut at age 4 years (adjOR 1.88, 95% CI: 1.03-3.44), and to house dust mite 
(HDM) at age 16 years (adjOR 0.47, 95% CI: 0.23-0.96), but not to other allergens. PSE was not 
an effect modifier, but a confounder, of the association between FLG mutation and IgE 
sensitization. Stratification by PSE and parental allergy resulted in minor differences. 
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Figure 14 Association between FLG mutation and IgE sensitization at age 4, 8, and 16 years. 
Children with data on PSE and FLG mutation were included (n=1,890). A logistic regression 
model with GEE adjusted for sex, parental allergy, and PSE was used. 
 
FLG mutation and pattern of IgE sensitization 
Among children with any IgE sensitization, mono-, oligo- and polysensitization did not differ 
significantly between children with and without FLG mutation. However, IgE antibodies to 
peanut were significantly more common among children with FLG mutation at age 4 years 
(43.3% vs. 22.3%, P=0.010), 8 years (36.0% vs. 21.8%, P=0.022), but not at 16 years (16.4% vs. 
17.1%, P=0.890), when analyzing the prevalence of IgE sensitization to each allergen 
separately. Children with FLG mutation in combination with PSE displayed the highest 
prevalence of IgE sensitization to peanut (Table 15). 
 
TABLE 15 IgE sensitization to peanut at 4, 8, and 16 years among children with preschool 
eczema (PSE+) and/or filaggrin mutation (FLG+).  
 
4 years  8 years  16 years 
 
IgE sensitization to peanut  IgE sensitization to peanut  IgE sensitization to peanut 
 
N % 95% CI  N % 95% CI  N % 95% CI 
PSE-/FLG- 
(reference)a 
25/161 16 10.3-22.1  48/324 15 11.1-19.2  47/387 12 9.1-15.8 
PSE+/FLG- 53/189 28 21.8-35.0  86/290 30 24.5-35.3  71/303 23 18.8-28.6 
PSE-/FLG+ 4/11 36 10.9-69.2  6/20 30 11.9-54.3  3/19 16 3.4-39.6 
PSE+/FLG+ 9/19 47 24.4-71.1  12/30 40 22.7-59.4  6/36 17 6.4-32.8 
aChildren without preschool eczema (PSE-) and FLG mutation (FLG-) were the reference. Significant 
differences in bold. 
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There were no other differences in IgE sensitization to single allergens when comparing 
children with and without FLG mutation. 
The cluster analysis performed on IgE sensitization to 14 allergens as dichotomous variables 
(positive or negative) did not provide any additional patterns of IgE sensitization associated 
with FLG mutation. As shown in Table 8, page 36, FLG mutation is equally frequent in both 
clusters. 
FLG mutation in relation to remission of PSE (IV) 
As stated above, among children with PSE FLG mutation is associated with reduced likelihood 
of complete remission at school age (crude OR 0.58, 95% CI: 0.36-0.93). 
FLG mutation in relation to ethnicity (additional data) 
The FLG mutations analyzed in studies III and IV were mutations known to be common in 
Scandinavia and Europe. A fraction of the children in studies III and IV had a parent born 
outside of Scandinavia (15.7% and 14.9%, respectively). To study this further, additional 
analyses were performed. In study III, 9.7% of the children had a parent born outside Europe. 
The analyzed FLG mutations were more common among children with European parents than 
those with a parent born outside Europe (7.8% [133 of 1,699] vs. 2.2% [4 of 183], P=0.005). 
The factor any parent born outside Europe was either a confounder, or an effect modifier, of 
the association between FLG mutation and IgE sensitization. When analyzing children with 
both parents being European separately a comparable result was seen (overall adjOR 0.99, 
95% CI: 0.72-1.37) as among all children together (overall adjOR 0.94, 95% CI: 0.68-1.28). In 
study IV, the corresponding prevalence of children with a non-European parent was 10.9%. 
The factor any parent born outside Europe was either a confounder or an effect modifier of 
the effect of FLG mutation on complete remission of preschool eczema. In conclusion, about 
10% in studies III and IV had a parent born outside Europe. This group of children had 
significantly lower prevalence of the FLG mutations studied. However, this finding did not 
influence the associations explored. 
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5 DISCUSSION 
MAIN FINDINGS 
Characteristics of eczema in adolescence (I) 
In the first study, we describe eczema among adolescents recruited from the general 
population. The 12-month prevalence of eczema was 9.7% at age 16-years, which is 
comparable with reports from other studies (7.3-13%).31-35, 131 As previously reported,12 onset 
was most common before age 2 years (48.8%). However, our study shows that onset of 
eczema is common (25.6%) also after 12 years of age, especially among adolescents with non-
AE. The British National Child Development Study have presented similar findings.37 
Of adolescents with eczema, more than one in four was classified as having moderate-to-
severe eczema. The prevalence of severe eczema (10.4%) was higher in our study compared 
with rates found in other population-based settings among children at preschool age (4-
6%).20, 27, 132 In these studies, severity was assessed using SCORAD and/or NESS. Previously in 
the BAMSE cohort, children with eczema at age 2 years were assessed using SCORAD 
(n=157)133 while the 12-year-old children were evaluated with the questionnaire scoring 
measurement BESS. These children were classified as having severe eczema at rates of 2% 
and 4%, respectively. The higher rates in our study could partly be explained by the fact that 
both BESS(3-12) and NESS reflect the severity of eczema over the preceding year, while 
SCORAD assesses the severity of current eczema. It has previously been shown that NESS 
provides higher rates of severe eczema than SCORAD.132 Another explanation could be that 
milder cases are more often in remission in adolescence and therefore the proportion of 
severe eczema cases may increase with age. In one American study of children 0-17 years the 
prevalence of severe eczema was 7%,108 which is comparable to our findings. To summarize, 
adolescents with eczema seems to have a larger proportion of severe eczema than younger 
children with eczema. 
The most common location of eczema in adolescence is flexural surfaces of extremities 
(creases), followed by neck and extensor surfaces of extremities. In literature, flexural 
location is common both in childhood and in adults, and extensor location is more common 
in infancy and childhood.3, 11 In adults, as well in small children, the face is a favored location,11, 
15, 134 but in our study the face was not among the most commonly reported locations. Even 
though facial involvement might be less common in adolescence, as many as one in five (20%) 
of the adolescents reported eczema located in the face. Facial involvement is probably of 
major concern to the adolescents due to its visibility and affected adolescents may be more 
likely to visit health care providers for this reason. 
AE was more common than non-AE in adolescence, and was more severe, had earlier onset 
and was more often connected to a history of chronic eczema throughout childhood. 
However, as regards to clinical signs such as location and seasonality of eczema, there were 
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no differences between AE and non-AE. In conclusion, in clinical practice, AE cannot be 
separated from non-AE without testing for IgE sensitization. Knowledge of IgE sensitization at 
an individual level will probably not change the management of an adolescent with eczema, 
unless the patient suffers from symptoms of asthma, rhinitis, contact urticarial or eczema 
caused by IgE sensitization, e.g., reaction to certain foods or HDM. 
The course of preschool eczema (IV) 
The cumulative prevalence of eczema before age 4 years (PSE) in our studies ranged between 
32.7% and 34.6%, which is comparable with other findings (cumulative prevalence at age 3 
years 33.5%,135 cumulative prevalence at age 2 years 14.2-21.5%18, 35). Half of children with 
PSE (51%) were in complete remission at school age, 8% had persistent eczema (eczema at all 
follow-ups) and 41% intermittent eczema (eczema in one or two of three follow-ups) at school 
age. In this population-based cohort, only half of children with eczema before age 4 years 
were free of symptoms at school age. According to a recent systematic review regarding 
remission of infantile eczema, only two studies were suitable for inclusion. One of these was 
based on the BAMSE material,93 while the other study reported complete remission up to age 
7 years among 43% of children with eczema before age 2 years.18 It is often said that small 
children outgrow their eczema.2 However, according to our findings this will be true only for 
half of them. Furthermore, some of the remitted cases will recur later in life, often as hand 
eczema,2 and the prognosis is probably even less favorable for children in specialist clinics. 
Factors of importance for remission of preschool eczema (IV) 
We were able to identify two factors positively associated with complete remission at school 
age: exclusive breastfeeding for at least 4 months and male sex.  Persistent eczema before 
age 4 years (PSE) and severe PSE (here eczema in combination with sleep disturbance due to 
itch) were both strongly associated with reduced likelihood of remission at school age. In 
addition, having a FLG mutation, parental allergy, and parental smoking were also significantly 
associated with reduced likelihood of remission; all analyses above were in multivariate 
models. These findings reflect the results of a systemic review and meta-analysis, in which 
persistence of eczema was associated with the factors persistent childhood eczema, more 
severe eczema, and female sex.42 Altogether, we identified at least two modifiable factors, 
parental smoking and exclusive breastfeeding ≥4 months. Encouragement to protect infants 
from passive smoking and to breastfeed exclusively for at least 4 months may improve the 
prognosis for children with PSE. Von Kobyletzki et al have highlighted the lack of knowledge 
regarding remission of eczema in a systematic review,43 and previous smaller studies have not 
found a significant association between either breastfeeding or parental smoking and 
remission of eczema.18, 136 To the best of our knowledge, our study is the largest to analyze 
the relationship between FLG mutation and prognosis of PSE in the general population, and 
the finding that FLG mutation is associated with reduced possibility for remission is novel. 
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The developed prognostic models for remission of PSE had a correct classification rate of 63-
65%. Thus, the factors included in the models were insufficient for full prediction of complete 
remission. The current knowledge is limited for disease prognosis at an individual level, and 
therefore further studies are warranted. 
Preschool eczema in relation to IgE sensitization (III) 
In study III, we clearly showed that PSE is associated with IgE sensitization to both food and 
aeroallergens up to age 16 years, possibly through skin barrier dysfunction. In addition, 
sensitized children with PSE more often had polysensitization compared with sensitized 
children without PSE. Other studies have mainly focused on associations between eczema 
and IgE sensitization to food allergens, with similar findings.87, 88 The Isle of Wight cohort 
explored if IgE sensitization to food and aeroallergens was associated with eczema up to age 
4 years, and their findings among 4-year-olds were comparable to ours.86 However, few other 
studies have analyzed IgE sensitization to aeroallergens in relation to eczema.  In our study, 
we were surprised to find that PSE was even more strongly associated with IgE sensitization 
to aeroallergens than that to food allergens. Notably, this association was strongest at 4 years 
of age, even though IgE sensitization to aeroallergens is more frequent later in childhood. 
Flohr et al found that the association between eczema and IgE sensitization to food was 
stronger with disease severity,82 and Perkin et al showed that persistent eczema up to age 5 
years was associated with IgE sensitization to food and/or aeroallergens at 5 years.89 We 
made similar findings and in our study the association was strongest between persistent PSE 
and IgE sensitization to food and aeroallergens. This result implies that the group with longer 
exposure regarding skin barrier dysfunction (children with persistent PSE) had the strongest 
association with IgE sensitization, which supports the idea of a causal relationship between 
skin barrier dysfunction and IgE sensitization. 
Filaggrin mutation in relation to eczema and IgE sensitization (III) 
According to the results in this thesis, having a FLG mutation was associated with 
development of eczema during childhood. Half of children with FLG mutation (49%) will 
develop eczema before age 4 years, which is significantly more than children without FLG 
mutation (33%). However, the majority (90%) of children with PSE did not have FLG mutation. 
The association between FLG mutation and eczema is previously well established.67 
One of the most important results in this thesis is that FLG mutation is not associated with IgE 
sensitization up to age 16 years, with the exception of IgE sensitization to peanut at age 4 
years. In contrast to our findings, an early systematic review showed that FLG mutation was 
associated with IgE sensitization,69 and Tan et al found that FLG mutation was associated with 
IgE sensitization to food also after adjusting for eczema.81 Furthermore, some studies have 
reported an association between FLG mutation and IgE sensitization to food allergens, but 
this association was not evident in the absence of prior eczema.70, 83 In line with our result, 
the most recent studies have not found an association between FLG mutation and IgE 
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sensitization to food.82, 84 However, one study has shown that FLG mutation is associated with 
peanut allergy independent of eczema.79 Another study found that exposure to peanut 
allergen early in life was associated with increased risk of IgE sensitization to peanut among 
children with FLG mutation, but not among children without FLG mutation.80 We found an 
association between FLG mutation and IgE sensitization to peanut at 4 years of age, but not 
at other ages. Altogether, these findings suggest that there is a relationship between FLG 
mutation and IgE sensitization to peanut, but not to other allergens. Our result implies that 
FLG mutation without PSE does not seem to play a major role in IgE sensitization either to 
food or to aeroallergens. Moreover, it is possible that skin barrier dysfunction due to FLG 
mutation is insufficient to cause IgE sensitization, with exception of peanut. 
Association between eczema and ADHD or CNS-associated disorders (II) 
We hypothesized that PSE, or eczema at other ages, could be associated with ADHD, as 
previously described by others.107-112 However, to our surprise, we did not find any significant 
association between PSE and ADHD medication at school age. In addition, neither infantile 
eczema, reported doctor’s diagnosis of PSE, severe PSE, persistent PSE, eczema at school age 
nor eczema ever up to age 16 years was associated with ADHD medication. On the other hand, 
we did not have sufficient power to detect associations with OR <1.5. Recent, larger studies 
among children have found significant, but weaker associations between eczema and 
ADHD137 or ADHD medication138, (adjOR 1.14, 95% CI: 1.03-1.16) and (HR 1.3, 95% CI: 1.2-1.5), 
respectively. Our study defined eczema based on parental report of symptoms in combination 
with report of doctor’s diagnosis whereas the other studies’ definitions were based on 
doctor’s diagnosis (reported or obtained from registers). Far from all children with symptoms 
of either eczema or ADHD have visited a doctor.17 Therefore, our results probably reflect the 
general population, including also milder cases of eczema, to a greater extent than the others, 
which might explain our findings. However, reported doctor’s diagnosis of eczema was not 
associated with ADHD medication in our study, and we believe that our large study with 
prospectively collected data is valid. To summarize, among children recruited from the 
general population, there is no strong association between eczema and ADHD medication. 
Finally, PSE was not associated with dispensed antidepressants, migraine drugs or 
antiepileptics. Before we started the analyses in study II only a few studies had been published 
regarding non-allergic comorbidities of eczema (e.g. cancer,139 epilepsy,114 depression108, 113). 
In the last few years, this research field has figuratively exploded. For example, studies have 
found that eczema is associated with increased risk for inflammatory bowel diseases and 
rheumatoid arthritis,106 hypertension,140 overweight (in North America and Asia, but not in 
Europe)141, and cardiovascular disease142, 143. A few published studies have reported an 
absence of association between eczema and non-allergic comorbidities, like two European 
studies that did not find an association between eczema and cardiovascular disease.144, 145 
Thus, it is possible that publication bias has favored papers that found an association. Based 
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on these findings in observational studies, researchers now suggest that eczema, like 
psoriasis, is a systemic disorder.146 Thus far, I am not convinced. While it would be appealing 
if new, effective treatments of eczema could prevent several of the proposed comorbidities, 
it is important to remember that statistical associations does not prove causality. 
METHODOLOGICAL CONSIDERATIONS 
In these studies, based on 4,089 children in a birth cohort recruited from the general 
population, we investigated associations between PSE and/or FLG mutation, and IgE 
sensitization, comorbidities, as well as remission of PSE later in childhood and adolescence. 
In addition, we could characterize eczema in adolescence, and explore the course of PSE up 
to age 16 years. The major strength was the population-based design with prospectively 
collected data regularly during 16 years of follow-up. Moreover, the large study size and the 
high number of participants that remained in the study during follow-up enabled us to 
perform subgroup analyses and stratification without lost power. The definition of eczema 
was based on questionnaire data, which can be a limitation. However, the longitudinal design 
with assessment of background factors and eczema at seven occasions over the course of 16 
years reduces the risk of misclassification of both exposures and outcomes. The access to data 
on IgE sensitization at 3 different ages, and FLG mutation for a majority of the children, as 
well as data on dispensed drugs by record linkage for all participants, were major advantages. 
The major considerations of this thesis are those associated with observational studies, and 
will be discussed below. 
Random errors 
Random error can occur in any study design, and originate from sampling variability. The risk 
for random error can be reduced by increasing the study size, which leads to a higher precision 
in the study. A high precision implies that there is a low risk that the observed results occurred 
by chance. The relatively large study population in the BAMSE cohort reduces the risk of 
random error. The overall narrow confidence intervals in the included studies implies good 
precision. In some of the stratified analyses and subgroup analyses, the results should be 
interpreted with caution due to small study groups. For example, when exploring IgE 
sensitization to peanut in relation to PSE and/or FLG mutation in study III, the wide confidence 
intervals indicate a large statistical uncertainty. 
Systematic errors (bias) 
In contrast to random errors, systematic errors do not depend on study size or chance. The 
most common systematic errors are selection bias, misclassification, and confounding. These 
can be introduced at all stages of the research process and lead to a reduced internal validity 
of the observed findings. The effects of bias is difficult to evaluate and take into account in 
analysis. For this reason, it is important to strive for a limited introduction of different biases 
during the research process, from initiating the study through evaluation of the results. 
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Nonetheless, systematic errors may occur and should be considered when interpreting the 
findings as well as the magnitude of their impact. Systematic error can cause both under- and 
overestimation of the associations studied.  
Selection bias 
Selection bias arises when the study population is not a representative sample of those 
theoretically eligible for the study (target population), and the association between exposure 
and outcome differs between those who participate and those who do not.147 Selection bias 
could have been introduced at three stages of the studies in this thesis. Firstly, at recruitment, 
a large proportion of the children were excluded according to study plan, for example those 
with a seriously ill child (n=57), or planning to move within 1 year (n=699). Of the 7,221 
children born in the predefined area, 76% (n=5,488) were eligible for inclusion. Secondly, of 
the eligible children, one in four did not respond or declined to participate, and 75% (n=4,089) 
were included in the study cohort. Two years after recruitment of the BAMSE project was 
initiated, a short questionnaire was mailed to families not included in the cohort. This 
additional study showed that non-participants more often reported parental smoking, but 
there were no other differences regarding parental allergy and other background 
characteristics when compared with participants.124 A large systematic review and meta-
analysis has shown that eczema is associated with passive smoking in children.53 Therefore, 
selection bias might have led to a small underestimation of eczema prevalence in our studies. 
When exploring associations within the cohort, non-participation has likely not introduced 
errors in the observed associations between exposure and outcome, since the comparisons 
are made within the cohort. However, in study I and study IV, where we described eczema in 
adolescence and the natural course of PSE, respectively, the prevalence rates probably do not 
fully reflect the true prevalence in the target population. 
Thirdly, in longitudinal studies selection bias might be introduced due to loss-to-follow-up. 
Loss-to-follow-up can bias the estimates of prevalence as well as the associations between 
exposure and outcome. In studies I-III, background characteristics of the study population 
were compared with the original cohort and there were minor differences in the prevalence 
of some characteristics. These differences were significant, but small, and likely did not affect 
the observed associations. Eczema, the main exposure/outcome of this thesis, might differ 
among those who continue to participate in our cohort compared with those who are lost to 
follow-up. Therefore, the prevalence rates in this thesis could have been either over- or 
underestimated due to loss-to-follow-up. However, in study I, 76% of the original cohort were 
included and the prevalence of eczema at age 1, 2, 4, 8, and 12 years did not significantly 
differ between the original cohort and the study population. Thus, the study population 
seems to be representative for the cohort and is probably not affected by selection bias. In 
the subpopulation of study II (n=2,736), PSE was more common among non-participants 
(n=964) compared with participants (41.3% vs. 31.9%). ADHD medication was also more 
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common among non-participants in the subpopulation (7.0% vs. 3.7%). This could have 
introduced selection bias. However, the investigated association between PSE and ADHD-
medication at school age did not differ between non-participants and participants ([adjOR 
0.96, 95% CI: 0.57-1.63] vs. [adjOR 1.16, 95% CI: 0.76-1.77]). Thus, the selection did not 
change the conclusion of study II. 
Misclassification 
Systemic errors in obtaining information (measurements or classifications) of the exposure 
and/or outcome once the participants have entered the study might lead to information bias, 
or misclassification. Information bias can be either differential, if the likelihood of being 
misclassified differs between the study groups, or non-differential. The differential 
information bias might either underestimate or exaggerate the association, while the effect 
of a non-differential information bias is random between the study groups and will dilute the 
true association (bias towards the null).  
Differential misclassification of the exposure is minimized in our studies because of the 
prospective design of the BAMSE cohort, with data on background factors and potential 
exposures collected before disease onset. Misclassification of eczema cannot be ruled out, 
especially after age 4 years. The most validated diagnostic criteria for eczema is based on 
clinical examination and diagnosis made by physicians.3, 4 In this thesis, the eczema definition 
is derived from questionnaire data. This definition has been validated at age 0-4 years and 
had high sensitivity (92%) and specificity (100%) when compared with clinical diagnosis by 
dermatologists.127 The BAMSE definition up to age 12 years is rather strict compared with 
other questionnaire-based definitions (e.g. the International Study of Asthma and Allergies in 
Childhood [ISAAC]),31 and require report of dry skin in combination with itchy rash on one to 
three specific body sites chosen among 14 specified body locations and/or reported doctor’s 
diagnosis of eczema since the preceding follow-up. This reduces the risk for misclassification 
in the eczema group. On the other hand, when compared with studies using doctor’s 
diagnosis of eczema (e.g., Genuneit et al)111, our definition probably includes milder cases. 
Altogether, our definition might underestimate the prevalence of eczema due to the strict 
criteria but include milder cases when compared with studies using doctor’s diagnosis 
(reported or register-based). At the clinical examination at 16 years in the BAMSE cohort, 
performed by trained nurses, the adolescents were asked for symptoms of eczema in the 
preceding week and examined for visible eczema. Almost half (48% [122 of 254]) of 
adolescents classified as having eczema in the questionnaire at age 16 years were diagnosed 
with current eczema and assessed for severity using POEM. Unfortunately, this cannot be 
used for validation of the questionnaire definition at the 16-year follow-up, since the disease 
is intermittent and the 12-month prevalence is not comparable with current eczema. 
However, in the ISAAC study, the questionnaire derived 12-month prevalence was compared 
with diagnosis of current eczema made by physician with similar findings (41.5% of children 
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fulfilling eczema in questionnaire had current eczema at examination). Furthermore, it was 
concluded that questionnaires provide adequate eczema prevalence estimates at population 
level.148 We cannot rule out that some of the children have contact dermatitis misclassified 
as eczema. Since the adolescents with eczema only at age 16 years (onset at 16 years) did not 
have higher rates of reported contact dermatitis compared with adolescents with eczema at 
age 16 years in combination with a history of eczema, this misclassification is probably of 
minor importance. In summary, the eczema definition is validated up to age 4 years, and 
misclassification of the definition is probably limited, with minor effects on the investigated 
associations. 
In study II, the definitions of ADHD and other CNS-associated disorders are based on 
dispensed drugs for each particular disease at school age (10-18 years). We have chosen to 
define the outcome as “ADHD medication at school age” since the definition will exclude 
children with ADHD medication before age 10 years, and children without medication. 
Misclassification can be introduced if a medication was prescribed and dispensed with some 
other indication (e.g. psychostimulants for rare disorders such as narcolepsy), but since such 
disorders are uncommon, this issue should be limited in our study. 
Confounding 
Confounding occurs when the association between an exposure and an outcome is 
attributable to a third factor (another exposure) which directly or indirectly causes the 
association. The confounding factor can lead to either a weaker or a stronger association. The 
prospective design of the BAMSE cohort, with collection of data on various background 
factors, and on allergy-related disorders and symptoms, enabled us to control for possible 
known and unknown confounders. 
In study I, we hypothesized that sex could be a confounding factor when investigating 
different aspects of adolescent eczema in relation to AE and non-AE. To control for sex, all 
analyses were performed both among all adolescent and stratified by sex when comparing 
AE with non-AE. Stratification by sex was also performed in studies II and III, and stratification 
by parental allergy was performed in study III with no major differences in the investigated 
associations. 
In studies II, III, and IV, we used logistic regression models and tested for confounding. Few 
factors tested changed the OR of the studied associations, and most factors were included in 
the adjusted model due to prior knowledge from literature. In study III, PSE was a significant 
confounding factor of the association between FLG mutation and IgE sensitization, and 
included in the final model. One could speculate that PSE is an intermediate link in the causal 
pathway between FLG mutation and IgE sensitization and therefore should not be classified 
as a confounder. However, the majority of all children with PSE (89.9%) do not have FLG 
mutations, indicating that PSE is not an intermediate link in most cases. In addition, there was 
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no major difference when comparing the association above with and without adjustment for 
PSE, and we chose to consider PSE a confounder. 
As additional data in this thesis, I have explored if ethnicity/having a parent born outside 
Europe is a confounder of associations involving FLG mutation. The analyses were restricted 
to children whose parents were both European and the restricted analyses were comparable 
with the full analysis. Moreover, adjustment for the factor Any parent born outside Europe 
did not change the OR of the investigated associations. 
As in all non-randomized studies, the influence of unmeasured and unknown confounders 
cannot be ruled out (residual confounding). 
Effect modification 
Effect modification, or interaction, occurs when the magnitude of the association between an 
exposure and an outcome depends on a third factor. In this situation, an overall estimate of 
the association will be misleading. To manage effect modification, the analysis can be 
stratified based on the third factor and the groups analyzed separately. 
We tested for possible effect modification in all logistic regression models (II, III, IV). In study 
III, both preschool asthma and preschool rhinitis were effect modifiers of the association 
between PSE and IgE sensitization up to 16 years. Consequently, we restricted the analysis to 
children without preschool asthma and preschool rhinitis. The restricted model displayed a 
lower point estimate compared with the full model, but the result was not significantly 
different. 
Generalizability 
Generalizability relates to whether or not the findings in the study population can be applied 
to other populations (external validity). Because of the study’s population-based design, good 
precision due to large study size, and limited selection bias, we assume that the associations 
found are generalizable to other urban European settings with high income, temperate 
climate, and comparable prevalence of eczema and background factors. On the other hand, 
the rates of eczema, may not reflect the area of recruitment since only 57% of children (4,089 
of 7,221) were actually included at baseline, and even fewer in our studies. Therefore, the 
generalizability of the prevalence of eczema and other disorders to other populations should 
be seen with caution. However, the prevalence of eczema in our studies corresponds fairly 
well with rates in other Swedish,31 Nordic,34 and European studies.18, 35, 89  
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6 CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES 
The high prevalence of severe eczema in adolescence is a large challenge. The explanation for 
the high rate could be that adolescents do not treat their eczema sufficiently. Their childhood 
eczema has been managed by parents and pediatric heath care, but is now supposed to be 
managed by the adolescents themselves, and care should be transferred to a general 
practitioner or dermatologist. An ongoing study in the BAMSE project preliminary indicates 
that the adolescents do not use enough TGCs in relation to reported symptoms.  If we can 
reduce the group of adolescents with severe eczema by only a few percent, a lot would be 
gained in health-related quality of life. Therefore, it would be most important to investigate 
the reasons for insufficient treatment by interviewing adolescents visiting health care due to 
eczema. Thereafter, an intervention study based on the observations in the interviews should 
be performed. For example, a secondary eczema educational program performed by nurses 
could be launched at age 12-14 years, focused on teaching eczema management. In addition, 
guidelines should be established for transferal from pediatric health care to suitable clinics 
that can support young adults with eczema. 
Severe and/or persistent eczema before age 4 years is strongly associated with persistence of 
eczema (non-remission) and with IgE sensitization later in childhood and adolescence. It has 
been showed that frequent use of emollients can delay onset of eczema among infants with 
high risk for eczema.56, 57 However, it is unknown whether anti-inflammatory treatment of 
eczema early in life affects the long-term prognosis and consequences of childhood eczema. 
To speculate, it is possible that new promising treatments64 can interfere with early disease 
persistency, resulting in a higher degree of remission and decreased prevalence of IgE 
sensitization. 
From a dermatologist point of view, comorbidities of eczema are seldom considered in clinical 
practice. Among children with eczema, I do think it is important to identify and manage 
symptoms of asthma and rhinitis within health care. Physicians meeting children with eczema 
should be aware of allergic comorbidities, ask about symptoms, and make sure that the 
children are treated and followed up adequately. I will have this in mind both as a physician 
and when I teach medical students and colleagues in the future. When it comes to non-allergic 
comorbidities of eczema, further research is needed before implementation in daily clinical 
practice. In the ongoing follow-up of the BAMSE cohort, we have asked about non-allergic 
disorders, including ADHD. I would like to re-evaluate the association between eczema and 
possible non-allergic comorbidities using data from the 22-24-year follow-up with record 
linkage to SPDR and national health care registers containing doctor’s diagnoses. 
The eczema definition used in the BAMSE cohort is not validated after 4 years of age. It would 
be most useful to perform a validation at the ongoing 22-24-year follow-up. For example, 
evaluate if William´s diagnostic criteria for atopic dermatitis performed by trained nurses or 
a dermatologist at the clinical examination is comparable with the eczema diagnosis derived 
from the preceding questionnaire. During the clinical examination at age 16 years, a patch 
test for common contact allergens was performed. Using this data, it would be interesting to 
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explore whether the adolescents with eczema have higher rates of allergic contact dermatitis 
than those without eczema, and if possible investigate if it is misclassified as eczema or occurs 
simultaneously with eczema within the BAMSE cohort.  
Why peanut? My findings indicate that IgE sensitization to peanut, but not to other allergens, 
seems to be associated with FLG mutation. A future study comparing the peanut allergen with 
other allergens in relation to skin barrier defects could be useful for understanding the 
possible mechanisms behind this finding. 
For me, it was a surprise to find that FLG mutation is not of major importance for IgE 
sensitization. Studies have reported that FLG mutation is associated not only with eczema, 
but also with allergy-related diseases (asthma and rhinitis).69, 70, 75 Since eczema is strongly 
associated with both FLG mutation, and with asthma and rhinitis, it is likely that eczema is 
either an effect modifier or a confounder on this association. It would be interesting to 
investigate the relationship between FLG mutation and allergy-related diseases, with similar 
methods as those used in study III, to provide additional knowledge within this research field. 
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7 CONCLUSIONS 
Almost 10% of Swedish adolescents report symptoms of eczema in the last year, and more 
than one in four has moderate-to-severe disease.  
Atopic eczema and nonatopic eczema in adolescence do not differ in location or seasonality. 
However, atopic eczema is more common than nonatopic eczema in adolescence, and is 
characterized by earlier onset, chronicity and more severe current eczema. Onset in 
adolescence is common, especially for nonatopic eczema. 
There is no significant association between preschool eczema, or eczema at any other time 
point up to age 16 years, and medication for ADHD at school age. In addition, there is no 
significant association between preschool eczema and medication for depression/anxiety 
/phobia, epilepsy or migraine at school age. 
Preschool eczema is associated with IgE sensitization, both to food and aeroallergens, up to 
age 16 years. This association is even stronger with persistent preschool eczema. In children 
with IgE sensitization, polysensitization is more common among those with preschool eczema 
than among those without. 
Filaggrin mutation is associated with IgE sensitization to peanut, but not to other allergens. 
This finding implies that filaggrin mutation without eczema early in life does not seem to play 
a major role in IgE sensitization. 
One third of children have eczema before age 4 years, and half of them (51%) are in complete 
remission at school age. 
Male sex and excusive breastfeeding for at least 4 months are positively associated with 
complete remission of preschool eczema at school age, whereas severe preschool eczema 
(reflected by persistency and/or sleep disturbance due to itch), parental allergy, parental 
smoking at child’s birth, and filaggrin mutation are all significantly associated with reduced 
likelihood of complete remission of preschool eczema. However, prognostic models are 
insufficient for the prediction of complete remission of preschool eczema at school age. 
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8 SVENSK SAMMANFATTNING 
Bakgrund 
Eksem (här synonymt med atopisk dermatit eller böjveckseksem) är en hudsjukdom som 
orsakar torr hud och återkommande episoder av röda, kliande hudutslag och som är vanlig 
hos barn och tonåringar. Barn med eksem har en ökad risk att insjukna i födoämnesallergi, 
astma och hösnuva, och har oftare IgE-antikroppar än barn utan eksem. Eksem med samtidig 
förekomst av IgE-antikroppar kallas för atopiskt eksem, annars för icke-atopiskt eksem. Flera 
studier visar att även vissa icke-allergiska sjukdomar, såsom ADHD, depression och epilepsi, 
är vanligare hos dem med eksem. Individer med en mutation i genen för filaggrin har ökad 
risk att insjukna i eksem, och det verkar som om de oftare har IgE-antikroppar jämfört med 
barn utan en sådan mutation. Man känner till många faktorer som gör att man fortsätter ha 
eksem senare i livet, men det saknas kunskap om vilka faktorer som har betydelse för att 
tillfriskna.  
Syfte 
Det övergripande syftet med denna avhandling var att beskriva eksem hos tonåringar, och att 
beskriva sjukdomsförloppet upp till 16 års ålder hos dem med eksem före 4 år. Vi ville också 
undersöka konsekvensen av att ha eksem före 4 års ålder och att ha en filaggrin-mutation, 
samt studera vilka faktorer som var av betydelse för att tillfriskna från eksem. 
Metoder 
Vi använde data från en svensk populationsbaserad födelsekohort (BAMSE) i vilken barnen 
(n=4,089) rekryterades från Storstockholm under perioden 1994-1996. Vid studiens start 
besvarade familjerna frågor om olika bakgrundsfaktorer. Då barnen var 1, 2, 4, 8, 12 och 16 
år fyllde föräldrarna i enkäter om bl.a. barnets eventuella eksem under de senaste 12 
månaderna, och barnen/tonåringarna besvarade egna enkäter vid 12 och 16 år. Blodprov 
samlades in vid kliniska undersökningar då barnen var 4, 8 och 16 år, och information om IgE-
antikroppar och filaggrin-mutation fanns för en majoritet av barnen. Registerdata för 
uthämtade receptbelagda läkemedel mot bl.a. ADHD och depression länkades till barnen i 
studien via Svenska läkemedelsregistret, och användes för att studera om dessa sjukdomar 
var vanligare hos barn med eksem. 
Resultat 
Vid 16 års ålder hade 10% (297 av 3,108) haft eksem de senaste 12 månaderna, och bland 
dessa klassificerades eksemet hos 73% som lindrigt, 17% som måttligt och 10% som svårt. 
Eksemen hos tonåringarna fanns oftast i böjveck (73%), på hals/nacke (40%) och på utsidan 
av armar och ben (39%). Nästan hälften (49%) av tonåringar med eksem hade fått sitt eksem 
före 2 års ålder, men för många debuterade eksemet först efter 12 år (26%). Hos 11% av alla 
tonåringar med eksem var detta kroniskt, dvs. det hade funnits vid alla tidigare uppföljningar 
i studien. Atopiskt eksem var vanligare än icke-atopiskt eksem. Tonåringar med atopiskt 
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eksem hade tidigare debut, svårare och oftare kroniskt eksem jämfört med dem som hade 
icke-atopiskt eksem, men det var ingen skillnad i säsongsvariation eller i eksemets 
lokalisation. 
ADHD-medicinering i skolåldern var inte vanligare bland barn som hade haft eksem före 4 års 
ålder (adjOR 1,12 [95% CI: 0,80-1,56]), och inte heller bland barn som hade haft eksem i andra 
åldrar jämfört med barn som inte haft eksem. Andra uthämtade receptbelagda läkemedel i 
skolåldern i form av antidepressiva, antiepileptika samt migränläkemedel var inte heller 
vanligare hos barn som haft eksem jämfört med dem utan eksem. 
Förekomst av IgE-antikroppar upp till 16 års ålder, både mot födoämnen och luftburna 
allergiframkallande ämnen, var dubbelt så vanlig hos dem som hade haft eksem före 4 års 
ålder jämfört med dem som inte hade haft eksem (adjOR 2,30 [95% CI: 2,00-2,66]). IgE-
antikroppar var vanligast bland barn som hade haft kroniskt eksem under sina första 4 
levnadsår. Hos barn med IgE-antikroppar vid 4, 8 och 16 år var förekomst av IgE-antikroppar 
mot flera olika allergen (polysensibilisering) vanligare hos barn som hade haft eksem före 4 
år än hos dem utan eksem. Barn med filaggrin-mutation hade inte oftare IgE-antikroppar än 
barn utan sådan mutation, med undantag av IgE-antikroppar mot jordnöt vid 4 års ålder 
(adjOR 1,88 [95% CI: 1,03-3,44]). 
Häften av alla barn (51%) som hade haft eksem före 4 år var eksemfria i skolåldern. Manligt 
kön och helamning i minst 4 månader var vanligare hos dem som var fria från eksem i 
skolåldern, medan kroniskt eksem och/eller svårt eksem upp till 4 års ålder, föräldrar med 
allergi-relaterad sjukdom, föräldrar som rökte vid tiden för barnets födelse och förekomst av 
filaggrin-mutation minskade chansen för att vara eksemfri i skolåldern.  
Slutsats 
Avhandlingen visar att endast hälften av alla barn som haft eksem någon gång under de första 
fyra levnadsåren är fria från eksem i skolåldern. Var tionde tonåring med eksem har svårt 
eksem. Till skillnad från tidigare studier hittade vi inget samband mellan eksem och uthämtat 
ADHD-läkemedel, antidepressiva, antiepileptika eller migränläkemedel i skolåldern. Barn med 
eksem före 4 år, framför allt de med kroniskt eksem, har oftare IgE-antikroppar senare i 
barndomen och tonåren jämfört med barn som inte haft eksem. Barn med filaggrin-mutation 
har oftare IgE-antikroppar mot jordnöt vid 4 års ålder, men inte mot andra vanliga 
allergiframkallande ämnen. Detta talar för att förekomst av en filaggrin-mutation, utan 
eksemsjukdom, inte verkar vara av stor betydelse för utvecklingen av IgE-antikroppar. 
Slutligen fann vi att manligt kön och helamning i minst 4 månader verkar öka möjligheten att 
tillfriskna från eksem, medan att ha haft ett kroniskt och/eller svårt eksem före 4 års ålder 
minskar chansen att vara eksemfri i skolåldern.
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